Hepion Pharmaceuticals Inc
Buy, Hold or Sell?

Let's analyse Hepion Pharmaceuticals Inc together

Penke I guess you are interested in Hepion Pharmaceuticals Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Hepion Pharmaceuticals Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Hepion Pharmaceuticals Inc

I send you an email if I find something interesting about Hepion Pharmaceuticals Inc.

Quick analysis of Hepion Pharmaceuticals Inc (30 sec.)

1. Valuation of Hepion Pharmaceuticals Inc (5 min.)

Live pricePrice per share (EOD)

$11.92

Book Value per Share

$0.65

2. Growth of Hepion Pharmaceuticals Inc (5 min.)

Is Hepion Pharmaceuticals Inc growing?

	Current year	Previous year	Grow	Grow %
How rich?	$49.8m	$98.2m	-$41.6m	-73.7%

How much money is Hepion Pharmaceuticals Inc making?

	Current year	Previous year	Grow	Grow %
Making money	-$10.5m	-$8.7m	-$1.8m	?
Net Profit Margin	0.0%	0.0%	-	-

How much money comes from the company's main activities?

Quarterly Yearly

3. Financial Health of Hepion Pharmaceuticals Inc (5 min.)

4. Comparing to competitors in the Biotechnology industry (5 min.)

Industry Rankings (Biotechnology)

Richest
#562 / 1215

Most Revenue
#931 / 1215

Most Profit
#674 / 1215

Most Efficient
#271 / 1215

Fundamentals of Hepion Pharmaceuticals Inc

Financial Health

Profitability Details

	Compared to previous year	Compared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.

Operating Efficiency Details

	Compared to previous year	Compared to industry

Liquidity Details

	Compared to previous year	Compared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.

Solvency Details

	Compared to previous year	Compared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

1.1. Profitability of Hepion Pharmaceuticals Inc.

1.1. Profitability

1.1.1. Net Profit Margin

Measures how much net profit Hepion Pharmaceuticals Inc earns for each $1 of revenue.

Above 10% is considered healthy but always compare Hepion Pharmaceuticals Inc to the Biotechnology industry mean.
A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Hepion Pharmaceuticals Inc:

The MRQ is 0.0%. The data is not here.

Trends

Current period		Compared to		+/-
MRQ	-	TTM	-	0.0%
TTM	-	YOY	-	0.0%
TTM	-	5Y	-	0.0%
5Y	-	10Y	-	0.0%

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	-	-194.7%	+194.7%
TTM	-	-273.6%	+273.6%
YOY	-	-315.2%	+315.2%
5Y	-	-539.0%	+539.0%
10Y	-	-664.9%	+664.9%

Measures how much net profit Hepion Pharmaceuticals Inc earns for each $1 of revenue.

Revenue is the amount of profit Hepion Pharmaceuticals Inc generates before taxes and all other costs. For example, when you buy a cup of coffee it will cost you $3. The company does not earn $3 in profit but also has to pay various costs and taxes to create that cup of coffee. Let's assume the cost of creating a cup of coffee is $1.5.

The $3 you pay for a cup of coffee is called revenue.
The $1.5 that’s left over when all costs to create that cup of coffee (including taxes) are deduced from the revenue is called net profit.

The net profit margin looks at how much net profit Hepion Pharmaceuticals Inc earns for each $1 in revenue.

How to use net profit margin

Higher profit margin is better (more profit).
Above 10% is considered healthy but always compare Hepion Pharmaceuticals Inc to the Biotechnology industry mean.
Can be used to compare companies within the Biotechnology industry.

You typically want a high profit margin. This means that for each $1 in sales, Hepion Pharmaceuticals Inc makes more profit. This shows the investor how efficiently Hepion Pharmaceuticals Inc is operating in general and compared to other companies in the same industry. Hepion Pharmaceuticals Inc operates in the Biotechnology industry.

Why do investors use net profit margin in their analysis

It helps investors to determine the efficiency of Hepion Pharmaceuticals Inc. If profit margins remain low (compared to the Biotechnology industry mean) and there are no improvements to make in production costs or other areas that might be a warning sign. If profit margins are high that means the company has low overhead costs and is efficiently using its resources to generate profit.

The three steps every investor should look at:

What is the current net profit margin?
The current most recent quarter (MRQ) Net Profit Margin of Hepion Pharmaceuticals Inc is 0.00. This means that Hepion Pharmaceuticals Inc earned $0.00 for each $1 in revenue in the most recent quarter.
How does it compare to the industry?
The mean MRQ Net Profit Margin of the Biotechnology industry is -194.7%.
What is the trend?
The trend is important because it shows you how Hepion Pharmaceuticals Inc is performing over time. The most recent quarter might be important if Hepion Pharmaceuticals Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Hepion Pharmaceuticals Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare Hepion Pharmaceuticals Inc with other companies in the same industry (Biotechnology).
Net profit margin should rise over the years.
Can be influenced when Hepion Pharmaceuticals Inc sells assets (profit will increase while costs remain the same).
It won’t show what part of Hepion Pharmaceuticals Inc is doing great or needs improvement (it only looks at total revenue and total net income).

How to calculate net profit margin

Net profit margin = net income / total revenue * 100%

Real example of Hepion Pharmaceuticals Inc

You need the following data to determine net profit margin:

Income statement from the period you want to calculate (for example, MRQ or TTM).

Net income MRQ Hepion Pharmaceuticals Inc = -6,811
Total revenue MRQ Hepion Pharmaceuticals Inc =
$-6,811 / $ = 0.00 or 0.0%

Higher is better

The higher the net profit margin, the more efficient the company is generating income. This helps investors to determine how the company is managing money. The net profit margin is an important indicator when diving into the financial health of a company. Overall, you want to see the net profit margin rising over the years. That means the company improved their production and made it more efficient (if possible).

You can use the net profit margin to compare companies within the same industry. If there are two companies where one is much bigger but the smaller one has a higher net profit margin, that means the smaller company is more efficiently using operational costs.

Important: Profit margins can be very different between industries. Companies with assembly lines or transports are much more prone to see shifting in prices for fuel, ingredients and maintenance compared to companies that only provide services. You should never compare net profit margin between different industries.

1.1.2. Return on Assets

Shows how efficient Hepion Pharmaceuticals Inc is using its assets to generate profit.

Above 5% is considered healthy but always compare Hepion Pharmaceuticals Inc to the Biotechnology industry mean.
-11.3% Return on Assets means that Hepion Pharmaceuticals Inc generated $-0.11 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Hepion Pharmaceuticals Inc:

The MRQ is -11.3%. Using its assets, the company is very inefficient in making profit. -2
The TTM is -14.7%. Using its assets, the company is very inefficient in making profit. -2

Trends

Current period		Compared to		+/-
MRQ	-11.3%	TTM	-14.7%	+3.4%
TTM	-14.7%	YOY	-8.1%	-6.6%
TTM	-14.7%	5Y	-13.4%	-1.3%
5Y	-13.4%	10Y	-89.8%	+76.4%

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	-11.3%	-12.4%	+1.1%
TTM	-14.7%	-12.5%	-2.2%
YOY	-8.1%	-10.9%	+2.8%
5Y	-13.4%	-15.3%	+1.9%
10Y	-89.8%	-17.6%	-72.2%

Shows how efficient Hepion Pharmaceuticals Inc is using its assets to generate profit.

For a farm, a tractor is considered an asset. The tractor helps ploughing the land making it possible to plant and harvest crops. But the tractor might be old and needing maintenance all the time reducing its efficiency. Return on assets indicates how effectively the farm is using the tractor (and other assets that help the core business) to plough the land.

How to use return on assets

Higher is better.
Above 5% is considered healthy but always compare Hepion Pharmaceuticals Inc to the Biotechnology industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use return on assets in their analysis

Shows the investor how effectively Hepion Pharmaceuticals Inc is using its resources to generate profit. If the return on assets (-11.3%) from Hepion Pharmaceuticals Inc are higher than the Biotechnology mean (-12.4%) that means Hepion Pharmaceuticals Inc is using its resources better than their competitors. If not, that means their competitors are more efficient in using their resources to generate profit.

An investor should always look at:

What is the current return on assets?
The current most recent quarter (MRQ) Return on Assets of Hepion Pharmaceuticals Inc is -11.3%. This means the company generated $-0.11 for each $1 in assets.
How does it compare to the industry?
The mean MRQ Return on Assets of the Biotechnology industry is -12.4%.
What is the trend?
The trend is important because it shows you how Hepion Pharmaceuticals Inc is performing over time. The most recent quarter might be important if Hepion Pharmaceuticals Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Hepion Pharmaceuticals Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
If a company has many assets changing over time, it’s better to calculate the average assets instead of the total assets.

How to calculate return on assets

Return on assets = net income / total assets * 100%

Real example Hepion Pharmaceuticals Inc

You need the following data to determine return on assets (ROA):

Income statement
Balance sheet

Net income MRQ (income statement) from Hepion Pharmaceuticals Inc = -6,811
Total assets MRQ (balance sheet) from Hepion Pharmaceuticals Inc = 60,244
-6,811 / 60,244 = -0.11 or -11.3%

ROA is an important ratio as it will tell you how effectively Hepion Pharmaceuticals Inc is using its resources to generate profits. Example:

Bob and Kristin both sell ice cream in the summer. They both have an ice cream truck. The truck Bob owes cost him $20.000 and the truck Kristin owes cost her $1500. Over the summer, Bob earned $2000 and Kristin earned $200. To calculate the return on assets:

Bob: $2000 / $20.000 * 100% = 10%
Kristin: $200 / $1500 * 100% = 13.3%

This tells you Bob’s company is more valuable but Kristin's company is more efficient. Be aware that total assets can change over time. A transportation business will buy and sell trucks or planes all the time. Before using return on assets as a guideline, you have to know what the exact assets are. For a company that has many assets changing over time, it’s better to calculate the average assets instead of the total assets.

1.1.3. Return on Equity

Shows how efficient Hepion Pharmaceuticals Inc is using its investors money to generate profit.

Above 15%-20% is considered healthy but always compare Hepion Pharmaceuticals Inc to the Biotechnology industry mean.
-13.7% Return on Equity means Hepion Pharmaceuticals Inc generated $-0.14 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Hepion Pharmaceuticals Inc:

The MRQ is -13.7%. Using its investors money, the company is very inefficient in making profit. -2
The TTM is -17.8%. Using its investors money, the company is very inefficient in making profit. -2

Trends

Current period		Compared to		+/-
MRQ	-13.7%	TTM	-17.8%	+4.2%
TTM	-17.8%	YOY	-8.9%	-9.0%
TTM	-17.8%	5Y	-29.5%	+11.6%
5Y	-29.5%	10Y	-51.3%	+21.8%

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	-13.7%	-15.2%	+1.5%
TTM	-17.8%	-15.5%	-2.3%
YOY	-8.9%	-13.1%	+4.2%
5Y	-29.5%	-20.4%	-9.1%
10Y	-51.3%	-20.9%	-30.4%

Shows how efficient Hepion Pharmaceuticals Inc is using its investors money to generate profit.

A publicly traded company (any company that issues shares to the public) is owned by its shareholders. Return on equity calculates the amount of profit for every $1 the shareholders invested.

How to use return on equity

Higher is better.
Above 15%-20% is considered healthy but always compare Hepion Pharmaceuticals Inc to the Biotechnology industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use return on equity in their analysis

To find out the owners/management's attitude toward their company. You typically want the owners/management to invest in the company and focus on generating profit. If not enough profit is generated (compared to the Biotechnology industry mean), the company might not be investing their money efficiently.

The three steps every investor should look at:

What is the current return on equity?
The current most recent quarter (MRQ) Return on Equity of Hepion Pharmaceuticals Inc is -13.7%. This means Hepion Pharmaceuticals Inc generated $-0.14 for each $1 the owners (shareholders) invested.
How does it compare to the industry?
The mean MRQ Return on Equity of the Biotechnology industry is -15.2%.
What is the trend?
The trend is important because it shows you how Hepion Pharmaceuticals Inc is performing over time. The most recent quarter might be important if Hepion Pharmaceuticals Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Hepion Pharmaceuticals Inc up to 10 years back (depending if Hepion Pharmaceuticals Inc existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
Does not include intangible assets (non physical assets like licences, computer software, etc.).
Stockholders equity and shareholders equity refer to the same thing.
Liabilities should not be more than three times return on equity.

How to calculate return on equity

Return on equity = net profit / shareholders equity * 100%

Real example of Hepion Pharmaceuticals Inc

You need the following data to determine ROE:

Income statement
Balance sheet
Net profit MRQ (income statement) Hepion Pharmaceuticals Inc = -6,811
Shareholders equity (balance sheet) MRQ Hepion Pharmaceuticals Inc = 49,856
-6,811 / 49,856 = -0.14 or -13.7%

A negative shareholder equity is a warning sign. It means the company has more liabilities than assets. It might also mean that the owners did not invest enough money or they are taking money out of the business.

1.2. Operating Efficiency of Hepion Pharmaceuticals Inc.

1.2. Operating Efficiency

1.2.1. Operating Margin

Measures how efficient Hepion Pharmaceuticals Inc is operating .

Measures how much profit Hepion Pharmaceuticals Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
Above 15% is considered healthy but always compare Hepion Pharmaceuticals Inc to the Biotechnology industry mean.
An Operating Margin of 0.0% means the company generated $0.00 for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Hepion Pharmaceuticals Inc:

The MRQ is 0.0%. The data is not here.

Trends

Current period		Compared to		+/-
MRQ	-	TTM	-	0.0%
TTM	-	YOY	-	0.0%
TTM	-	5Y	-	0.0%
5Y	-	10Y	-	0.0%

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	-	-318.9%	+318.9%
TTM	-	-267.4%	+267.4%
YOY	-	-333.8%	+333.8%
5Y	-	-517.0%	+517.0%
10Y	-	-624.7%	+624.7%

Measures how efficient Hepion Pharmaceuticals Inc is operating .

The more effecient a company creates products or provides services, the more profit it generates.

How to use operating margin

Higher is better
Above 15% is considered healthy but always compare Hepion Pharmaceuticals Inc to the Biotechnology industry mean.
Can be very different between industries
Can be used to compare companies

Why do investors use operating margin in their analysis

To determine how much profit Hepion Pharmaceuticals Inc is making from it’s core business.

The three steps every investor should look at:

What is the current net profit margin?
The current most recent quarter (MRQ) Operating Margin of Hepion Pharmaceuticals Inc is 0.0%. This means that Hepion Pharmaceuticals Inc earned $0.00 for each $1 in revenue in the most recent quarter.
How does it compare to the industry?
The mean MRQ Operating Margin of the Biotechnology industry is -318.9%.
What is the trend?
The trend is important because it shows you how Hepion Pharmaceuticals Inc is performing over time. The most recent quarter might be important if Hepion Pharmaceuticals Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Hepion Pharmaceuticals Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry
Can be calculated in different ways

How to calculate operating margin

Operating margin = operating earnings / total revenue

Real example of Hepion Pharmaceuticals Inc

You need the following data to determine operating margin:

Income statement
Operating earnings MRQ Hepion Pharmaceuticals Inc = -9,773
Total revenue MRQ Hepion Pharmaceuticals Inc =
$-9,773 / $ = 0.00 or 0.0%

Operating margin is used to calculate how much profit a company makes after variable costs of production but before paying interest and taxes. Some variable costs examples are wages, raw materials, packaging, and transaction fees. The amount of variable costs is different for each company and industry. In general, a higher operating margin is better as this implicates that a company is running efficiently.

For investors, a higher operating margin is a good sign. Although you should always look at operating margin in the long term. If operating margin is fluctuating over the years this might be a sign that things are not running efficiently enough. It’s a way to check how much profit a company is making from its core business.

Operation earnings can be calculated in multiple ways:

Operation earnings = EBIT - non operating income + non operating expense
Operation earnings = Gross profit - operating expense - depreciation and amortisation
Operation earnings = Total revenue - COGS (costs of goods sold) - indirect costs

1.2.2. Operating Ratio

Measures how efficient Hepion Pharmaceuticals Inc is keeping operating costs low.

Below 1 is considered healthy (always compare to Biotechnology industry mean).
An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Hepion Pharmaceuticals Inc:

The MRQ is 0.000. The data is not here.

Trends

Current period		Compared to
MRQ	-	TTM	-
TTM	-	YOY	-
TTM	-	5Y	-
5Y	-	10Y	-

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	-	3.013	-3.013
TTM	-	3.644	-3.644
YOY	-	4.537	-4.537
5Y	-	6.411	-6.411
10Y	-	8.312	-8.312

Measures how efficient Hepion Pharmaceuticals Inc is keeping operating costs low.

If the operating ratio is below 1 that means the company is making money. The lower the operating ratio, the more efficient the company.

How to use operating ratio

Lower is better.
Below 1 is considered healthy but always compare Hepion Pharmaceuticals Inc to the Biotechnology industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use operating ratio in their analysis

Shows if costs of creating products and or services is increasing or decreasing. The lower the operating ratio, the more efficient the company is creating products and services.

The three steps every investor should look at:

What is the current Operatin ratio?
The current most recent quarter (MRQ) Operating Ratio of Hepion Pharmaceuticals Inc is 0.0%. This means that Hepion Pharmaceuticals Inc earned $0.00 for each $1 in net sales in the most recent quarter.
How does it compare to the industry?
The mean MRQ Operating Ratio of the Biotechnology industry is 3.01.
What is the trend?
The trend is important because it shows you how Hepion Pharmaceuticals Inc is performing over time. The most recent quarter might be important if Hepion Pharmaceuticals Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Hepion Pharmaceuticals Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
You need COGS to calculate operating ratio which is not always shown in the income statement.
Does not consider debt.

How to calculate operating ratio

Operating ratio = Operating expenses + COGS \ Net sales

Real life example Hepion Pharmaceuticals Inc

You need the following data to determine operating ratio:

Income statement

COGS is not always specified on the income statement. If so you can use the following calculation:

(cost of revenue + total operating expenses) \ total revenue
( +7,902) \ = 0.00

The operating ratio measures the efficiency of a company at keeping low costs while generating profits from sales. It compares the total operating expenses to the net amount of sales. The total operating expenses exists of:

COGS (materials, labour, rent of facility, repairs)
Operating expenses (legal fees, marketing, wages, rent, maintenance/repairs)

Operating expenses are all the costs the company makes that are not directly tied to the production of the service or product. Where COGS are costs that are directly tied to the production of a product or service.

Do note that COGS is not always available in the income statement. Some companies include COGS in the operating expenses while others list COGS separately. To make it even more confusing, COGS is also known as “costs of sales” and costs of sales is the same as costs of revenue.

The operating ratio tells you how efficient the company is creating its products or services while keeping prices low. In this case, a lower ratio is better. Higher or rising operating ratios might tell you that costs are rising while sales are not improving or staying the same.

1.3. Liquidity of Hepion Pharmaceuticals Inc.

1.3. Liquidity

1.3.1. Current Ratio

Measures if Hepion Pharmaceuticals Inc is able to pay off Short-term Debt.

Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
A Current Ratio of 7.16 means the company has $7.16 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Hepion Pharmaceuticals Inc:

The MRQ is 7.164. The company is very able to pay all its short-term debts. +2
The TTM is 7.261. The company is very able to pay all its short-term debts. +2

Trends

Current period		Compared to		+/-
MRQ	7.164	TTM	7.261	-0.096
TTM	7.261	YOY	14.280	-7.019
TTM	7.261	5Y	9.674	-2.414
5Y	9.674	10Y	6.870	+2.804

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	7.164	4.559	+2.605
TTM	7.261	4.993	+2.268
YOY	14.280	6.149	+8.131
5Y	9.674	6.306	+3.368
10Y	6.870	6.588	+0.282

Measures if Hepion Pharmaceuticals Inc is able to pay off Short-term Debt.

How to use current ratio

Higher is better
Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
Can be very different between industries
Can be used to compare companies

Why do investors use current ratio in their analysis

Shows if the company can pay of short term debts if needed. A company that can't pay off it's short term debts might get in trouble if they have to pay off their short term debts for whatever reason. For example, markets can change due to global events like covid-19 or the war in Ukraine versus Russia. Because debts are always taken based on future income, it might become troublesome for Hepion Pharmaceuticals Inc if something happens in the market that will cause sales to plummet.

The three steps every investor should look at:

What is the current current Ratio?
The current most recent quarter (MRQ) Current Ratio of Hepion Pharmaceuticals Inc is 7.16. This means Hepion Pharmaceuticals Inc has $7.16 in assets for each $1 in short-term debts.
How does it compare to the industry?
The mean MRQ Current Ratio of the Biotechnology industry is 4.56.
What is the trend?
The trend is important because it shows you how Hepion Pharmaceuticals Inc is performing over time. The most recent quarter might be important if Hepion Pharmaceuticals Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Hepion Pharmaceuticals Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
Might be deluded.
Not all assets can always be quickly sold.
Can be manipulated by increasing or decreasing the assets and/or liabilities.

How to calculate current ratio

Current ratio = current assets \ current liabilities

Real life example Hepion Pharmaceuticals Inc

You need the following data to determine operating ratio:

Balance sheet
Current ratio = current assets \ current liabilities
56,496 \ 7,886) = 7.16

The current ratio measures if Hepion Pharmaceuticals Inc is able to pay short-term debts (obligations). Short term in this context means all debt obligations that are about to expire within one year. The current ratio incorporates current liabilities and current assets. Current assets are all the assets a company has that are expected to be consumed or sold within standard business operations. You can find the current assets in the balance sheet. They consist of:

Inventory
Accounts receivable
Marketable securities
Prepaid expenses
Cash
Cash equivalents
liquid assets

The current liabilities are short term obligations that are due within one year. These consist of:

Short term debts
Dividends
Income taxes
Short-term debts
Accounts payable
Interest payments

The result shows an investor if Hepion Pharmaceuticals Inc is able to pay all its short-term debts if they were due all at once. When the result of the above formula is below 1, then Hepion Pharmaceuticals Inc does not have enough capital after selling all its assets to pay all short-term debts. If the ratio drops far below 1 that might indicate Hepion Pharmaceuticals Inc is or will be in financial trouble anytime soon.

Although this gives an investor some clues, the current ratio may also be deluded. Because owning assets does not mean the company can easily sell them. Also, Accounts receivable may be quite old (they will probably never pay) which deludes the current ratio. As with all ratios, you should only compare them between the same industries and companies.

1.3.2. Quick Ratio

Measures if Hepion Pharmaceuticals Inc is able to pay off Short-term Debt but only using the most liquid assets.

Above 1 is considered healthy but always compare Hepion Pharmaceuticals Inc to the Biotechnology industry mean.
A Quick Ratio of 6.49 means the company can pay off $6.49 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Hepion Pharmaceuticals Inc:

The MRQ is 6.491. The company is very able to pay all its short-term debts with the most liquid assets. +2
The TTM is 4.937. The company is very able to pay all its short-term debts with the most liquid assets. +2

Trends

Current period		Compared to		+/-
MRQ	6.491	TTM	4.937	+1.554
TTM	4.937	YOY	10.525	-5.587
TTM	4.937	5Y	8.315	-3.378
5Y	8.315	10Y	6.032	+2.283

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	6.491	3.881	+2.610
TTM	4.937	4.502	+0.435
YOY	10.525	5.772	+4.753
5Y	8.315	5.816	+2.499
10Y	6.032	6.032	0.000

Measures if Hepion Pharmaceuticals Inc is able to pay off Short-term Debt but only using the most liquid assets.

How to use quick ratio

Higher is better.
Above 1 is considered healthy but always compare Hepion Pharmaceuticals Inc to the Biotechnology industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use quick ratio in their analysis

Shows how fast Hepion Pharmaceuticals Inc can pay off its short term debts. This shows if Hepion Pharmaceuticals Inc can survive emergencies due to market changes or other reasons.

The three steps every investor should look at:

What is the current Quick Ratio?
The current most recent quarter (MRQ) quickRatio of Hepion Pharmaceuticals Inc is 6.49. This means that Hepion Pharmaceuticals Inc can pay off $6.49 for each $1 in debt (using most liquid assets).
How does it compare to the industry?
The mean MRQ Quick Ratio of the Biotechnology industry is 3.88.
What is the trend?
The trend is important because it shows you how Hepion Pharmaceuticals Inc is performing over time. The most recent quarter might be important if Hepion Pharmaceuticals Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Hepion Pharmaceuticals Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
Incorporates only most liquid assets.

How to calculate quick ratio

Quick ratio = cash and equivalents + marketable securities + accounts receivable / current liabilities

Real life example Hepion Pharmaceuticals Inc

You need the following data to determine operating ratio:

Balance sheet
Quick ratio = cash and short-term investments + short-term investments + netReceivables / total current liabilities
MRQ quick ratio Hepion Pharmaceuticals Inc: (51,189 + +) / 7,886 = 6.49

The quick ratio measures the same thing as the current ratio, only it uses the most liquid assets a company has. Meaning, the assets that can be sold for cash the easiest and fastest.

As the quick ratio only incorporates the most liquid assets, you should also check the current ratio which also includes less liquid assets. But they may be harder to sell.

1.4. Solvency of Hepion Pharmaceuticals Inc.

1.3. Liquidity

1.4.1. Debt to Asset Ratio

Measures how much % of Hepion Pharmaceuticals Inc assets are financed with debt.

Below 1 (100%) is considered healthy but always compare Hepion Pharmaceuticals Inc to Biotechnology industry mean.
A Debt to Asset Ratio of 0.17 means that Hepion Pharmaceuticals Inc assets are financed with 17.2% credit (debt) and the remaining percentage (100% - 17.2%) is financed by its owners/shareholders.

Let's take a look of the Debt to Asset Ratio trends of Hepion Pharmaceuticals Inc:

The MRQ is 0.172. The company is very able to pay all its debts by selling its assets. +2
The TTM is 0.172. The company is very able to pay all its debts by selling its assets. +2

Trends

Current period		Compared to		+/-
MRQ	0.172	TTM	0.172	+0.000
TTM	0.172	YOY	0.088	+0.084
TTM	0.172	5Y	0.309	-0.137
5Y	0.309	10Y	2.165	-1.855

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	0.172	0.311	-0.139
TTM	0.172	0.298	-0.126
YOY	0.088	0.269	-0.181
5Y	0.309	0.377	-0.068
10Y	2.165	0.409	+1.756

Measures how much % of Hepion Pharmaceuticals Inc assets are financed with debt.

When there are more debts than assets, that means creditors have a larger stake Hepion Pharmaceuticals Inc than its shareholders.

How to use debt to asset ratio

Lower is better.
below 1 (100%) is considered healthy but always compare Hepion Pharmaceuticals Inc to Biotechnology industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use the debt to asset ratio in their analysis

It shows how much debt the company used to finance its assets. If a company is almost entirely financed with debt that means the company might get into serious trouble when emergencies arise like a raise in interest.

The three steps every investor should look at:

What is the current debt to asset ratio?
The current most recent quarter (MRQ) Debt to Asset Ratio of Hepion Pharmaceuticals Inc is 0.17. This means means that Hepion Pharmaceuticals Inc is financed with 17.2% credit and the remaining percentage is financed by it's owners (shareholders).
How does it compare to the industry?
The mean MRQ Current Ratio of the Biotechnology industry is 455.9%.
What is the trend?
The trend is important because it shows you how Hepion Pharmaceuticals Inc is performing over time. The most recent quarter might be important if Hepion Pharmaceuticals Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Hepion Pharmaceuticals Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry
Some companies can have higher debt to assets ratio's (for example, banks).
Debt to asset ratio should improve over the years.
If the debt to asset ratio is above 1, look at the industry mean and find out why Hepion Pharmaceuticals Inc has so much debt.

How to calculate debt to asset ratio

Debt to asset ratio = total debt \ total assets

Real life example Hepion Pharmaceuticals Inc

You need the following data to determine debt to asset ratio:

Balance sheet
Debt to asset ratio = total debt \ total assets
10,389 \ 60,244 = 17.2% or 0.17.

The debt to total assets ratio shows if the company is owned by creditors or shareholders. Or in other words, the total debt in relation to the total amount of assets. It shows how much debt the company used to finance its assets.

1.4.2. Debt to Equity Ratio

Measures if Hepion Pharmaceuticals Inc is able to pay off its debts by using shareholders equity.

Below 2 is considered healthy but always compare Hepion Pharmaceuticals Inc to the Biotechnology industry mean.
A Debt to Equity ratio of 20.8% means that company has $0.21 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Hepion Pharmaceuticals Inc:

The MRQ is 0.208. The company is very able to pay all its debts with equity. +2
The TTM is 0.209. The company is very able to pay all its debts with equity. +2

Trends

Current period		Compared to		+/-
MRQ	0.208	TTM	0.209	0.000
TTM	0.209	YOY	0.097	+0.111
TTM	0.209	5Y	0.999	-0.790
5Y	0.999	10Y	1.131	-0.133

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	0.208	0.363	-0.155
TTM	0.209	0.362	-0.153
YOY	0.097	0.277	-0.180
5Y	0.999	0.424	+0.575
10Y	1.131	0.463	+0.668

Measures if Hepion Pharmaceuticals Inc is able to pay off its debts by using shareholders equity.

How to use debt to equity ratio

Lower is better.
Below 2 is considered healthy (always use industry average).
Can be very different between industries.
Can be used to compare companies.

Why do investors use the debt to shareholders equity ratio in their analysis

It shows how much debt the company uses to finance their operations. Shareholders equity is whats left over when you subtract total liabilities from total assets. It's another way to meassure how much of Hepion Pharmaceuticals Inc is financed with debt or own resources.

The three steps every investor should look at:

What is the current debt to equity ratio?
The current most recent quarter (MRQ) quickRatio of Hepion Pharmaceuticals Inc is 0.21. This means that Hepion Pharmaceuticals Inc can pay off $0.21 for each $1 in debt.
How does it compare to the industry?
The mean MRQ Quick Ratio of the Biotechnology industry is 0.36.
What is the trend?
The trend is important because it shows you how Hepion Pharmaceuticals Inc is performing over time. The most recent quarter might be important if Hepion Pharmaceuticals Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Hepion Pharmaceuticals Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
Not all debt is equally risky (for example, short term risk is less risky).

How to calculate debt to equity ratio

Debt to equity ratio = total debt \ shareholders equity.

Real life example Hepion Pharmaceuticals Inc

You need the following data to determine equity ratio:

Balance sheet
Debt to equity ratio = total debt \ shareholders equity
10,389 \ 49,856 = 0.21 or 20.8%

Debt to equity measures the total debt versus the total shareholders equity. While the total debts to total assets ratio uses total assets, the debt to equity ratio looks at the total equity of shareholders. Where equity of shareholders are:

Common shares.
Preferred shares.
Retained earnings.

You can find the shareholders' equity in the balance sheet. A ratio between 0,5 and 1,5 is preferred. If the ratio is above 1.5, that would indicate creditors have significantly more stake (debt) in the company than the shareholders. In other words, the company is using a lot of debt to finance their operations.

Not all debt is equally risky. Meaning you can adjust the ratio by including or excluding certain amounts of debt. Short term debts are less risky because they have to be paid back within one year anyway. It’s much easier to plan one year ahead versus five or ten years.

2. Market Valuation of Hepion Pharmaceuticals Inc

2. Earnings Per Share

2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Hepion Pharmaceuticals Inc generates.

Above 15 is considered overpriced but always compare Hepion Pharmaceuticals Inc to the Biotechnology industry mean.
A PE ratio of -8.69 means the investor is paying $-8.69 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Hepion Pharmaceuticals Inc:

The EOD is -133.401. Company is losing money. -2
The MRQ is -8.690. Company is losing money. -2
The TTM is -4.687. Company is losing money. -2

Trends

Current period		Compared to		+/-
EOD	-133.401	MRQ	-8.690	-124.711
MRQ	-8.690	TTM	-4.687	-4.003
TTM	-4.687	YOY	-13.850	+9.163
TTM	-4.687	5Y	-32.943	+28.256
5Y	-32.943	10Y	-32.064	-0.879

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
EOD	-133.401	-6.504	-126.897
MRQ	-8.690	-7.165	-1.525
TTM	-4.687	-8.417	+3.730
YOY	-13.850	-19.810	+5.960
5Y	-32.943	-18.328	-14.615
10Y	-32.064	-18.049	-14.015

Measures how much money you pay for each share for every $1 in earnings Hepion Pharmaceuticals Inc generates.

Indicates if the company’s shares are under or overvalued.

How to use PE ratio

Above 15 is considered overpriced but is hard to determine. Always compare Hepion Pharmaceuticals Inc to the Biotechnology industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use PE ratio in their analysis

The PE ratio tells investors the current sentiment in the market for that company. As with every stock, the stock price never shows the real valuation of a company but rather how the market thinks how much the stock is worth.

In other words, the current stock price also incorporates any future earnings or business opportunities in the future. The best example is the stock market crash in 2000. The PE ratio for any internet based company was going through the roof. Only based on the general assumption the internet and all associated businesses would thrive in the future. But this was based on nothing. A business still needs a good product or service to be able to survive. Instead, every investor bought any stock which did something related to the internet. Result: huge market crash.

Many investors were willing to pay premium prices and that was causing the PE ratio to rise. A high PE ratio is a warning sign that investors might be overvaluing a stock based on future earnings.

The three steps every investor should look at:

What is the current PE Ratio?
The current most recent quarter (MRQ) PE Ratio of Hepion Pharmaceuticals Inc is -8.69. This means the investor is paying $-8.69 for every $1 in earnings.
How does it compare to the industry?
The mean MRQ Quick Ratio of the Biotechnology industry is -7.17.
What is the trend?
The trend is important because it shows you how Hepion Pharmaceuticals Inc is performing over time. The most recent quarter might be important if Hepion Pharmaceuticals Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Hepion Pharmaceuticals Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
Some industries might have very high or very low PE ratios in general.
PE ratios can be high for several years, it does not mean a sudden collapse is imminent.
Earnings growth is not included in the PE ratio.

How to calculate PE ratio

PE ratio = market value per share \ earnings per share

Real life example Hepion Pharmaceuticals Inc

You need the following data to determine the PE ratio:

Balance sheet
Income statement

The PE ratio is a very commonly used ratio to determine the value of a company by comparing the current stock price relative to its earnings per share (EPS). Before we can calculate the PE ratio we need to know the EPS. EPS is calculated as follows:

EPS = (net profit - preferred dividends) \ end of period outstanding shares*
Net profit = revenue - expenses
\ 0 = EPS
PE ratio MRQ = -8.69

* The net profit minus preferred dividends can be found in the incomestatement as netIncomeApplicableToCommonShares.

The PE value helps investors to determine if the current stock price is under or overvalued. It also projects future growth.

In general, a higher PE ratio means that investors predict higher future growth. If the PE ratio is too high, then investors expect way too much future growth the company can never fulfil. This is most likely to happen in faster moving companies like tech companies or automobile companies like Tesla. These are hot and booming markets where investors expect much future growth driven by new technology (electric cars). When looking at the current MRQ (most recent quarter) PE ratio of Tesla ( jan. 2021) it's about 247 while the average in the industry is only 6. That might be a clue that Tesla is trading for way too high prices compared to their current assets and is more based on future growth.

2.2. Price Earnings to Growth Ratio

Measures the predicted future growth of Hepion Pharmaceuticals Inc.

Lower is better.
A PEG ratio of 1 means the market price of the stock and the expected future earnings are on par.

Let's take a look of the Price Earnings to Growth Ratio trends of Hepion Pharmaceuticals Inc:

The MRQ is -8.690. Very Bad. -2
The TTM is -2.961. Very Bad. -2

Trends

Current period		Compared to		+/-
MRQ	-8.690	TTM	-2.961	-5.730
TTM	-2.961	YOY	-15.775	+12.814
TTM	-2.961	5Y	-19.153	+16.192
5Y	-19.153	10Y	-18.412	-0.740

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	-8.690	-4.287	-4.403
TTM	-2.961	-6.137	+3.176
YOY	-15.775	-13.849	-1.926
5Y	-19.153	-12.525	-6.628
10Y	-18.412	-11.713	-6.699

PEG Ratio	Meaning
0.5	You can buy the stock cheap based on future growth
1	You pay a fair price based on future growth
2	The stock is overpriced based on future growth

2. Book Value per Share

2.3. Price to Book Ratio

Measures if the stock price of Hepion Pharmaceuticals Inc is to cheap or to expensive compared to its book value.

At or below 1 is considered healthy (always compare to Biotechnology industry mean).
A PB ratio of 1.19 means the investor is paying $1.19 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Hepion Pharmaceuticals Inc:

The EOD is 18.226. Seems overpriced? -1
The MRQ is 1.187. Good. +1
The TTM is 0.736. Very good. +2

Trends

Current period		Compared to		+/-
EOD	18.226	MRQ	1.187	+17.038
MRQ	1.187	TTM	0.736	+0.451
TTM	0.736	YOY	1.142	-0.406
TTM	0.736	5Y	1.026	-0.290
5Y	1.026	10Y	-0.570	+1.596

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
EOD	18.226	1.991	+16.235
MRQ	1.187	2.024	-0.837
TTM	0.736	2.335	-1.599
YOY	1.142	3.965	-2.823
5Y	1.026	3.738	-2.712
10Y	-0.570	4.004	-4.574

2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Hepion Pharmaceuticals Inc.

3.1. Institutions holding Hepion Pharmaceuticals Inc

Institutions are holding 9.381% of the shares of Hepion Pharmaceuticals Inc.

Date	Name	Total Shares	Total Assets	Current Shares	Change	%
2022-12-31	Vanguard Group Inc	4.3424	0	3310180	1657	0.0501
2022-12-31	BlackRock Inc	2.0957	0	1597566	4785	0.3004
2022-12-31	Geode Capital Management, LLC	0.8612	0	656453	-1657	-0.2518
2022-12-31	State Street Corporation	0.4113	0	313500	0	0
2022-12-31	Renaissance Technologies Corp	0.3222	0.0001	245600	13500	5.8165
2022-12-31	Envestnet Asset Management Inc	0.2663	0	202978	115437	131.8662
2022-12-31	Northern Trust Corp	0.1732	0	132059	0	0
2022-12-31	Susquehanna International Group, LLP	0.1258	0	95929	-69261	-41.9281
2022-12-31	Bank of New York Mellon Corp	0.1164	0	88715	-69502	-43.9283
2022-12-31	Morgan Stanley - Brokerage Accounts	0.1055	0	80403	62996	361.9004
2023-03-31	McAdam, LLC	0.0816	0.0044	62169	1	0.0016
2022-12-31	PNC Financial Services Group Inc	0.0756	0	57594	60	0.1043
2022-12-31	Advisor Group Holdings, Inc.	0.0442	0	33701	2608	8.3877
2022-12-31	Tower Research Capital LLC	0.0424	0.0004	32289	12323	61.7199
2022-12-31	Charles Schwab Investment Management Inc	0.0414	0	31535	0	0
2022-12-31	Cetera Investment Advisers	0.039	0.0001	29732	18459	163.7452
2022-12-31	Two Sigma Advisers, LLC	0.034	0	25900	-4200	-13.9535
2022-12-31	Group One Trading, LP	0.0319	0	24336	-1900	-7.242
2022-12-31	Virtu Financial LLC	0.0278	0.0008	21165	-46637	-68.7841
2023-03-31	Amplius Wealth Advisors, LLC	0.0131	0.0011	10000	0	0
Total		9.251	0.0069	7051804	+38669	+0.5%

3.2. Funds holding Hepion Pharmaceuticals Inc

Date	Name	Total Shares	Total Assets	Current Shares	Change	%
2023-03-31	Vanguard Total Stock Mkt Idx Inv	2.7166	0.0001	2070833	0	0
2022-12-31	Vanguard Instl Ttl Stck Mkt Idx Tr	2.7166	0.0001	2070833	0	0
2023-03-31	Vanguard Extended Market Index Investor	1.4309	0.001	1090743	0	0
2023-02-28	Fidelity® Extended Market Index	0.5226	0.0011	398350	0	0
2023-03-31	iShares Micro-Cap ETF	0.2132	0.0141	162526	0	0
2023-02-28	Fidelity® Total Market Index	0.1382	0.0001	105370	0	0
2023-02-28	Vifag 2002 SICAV	0.1312	0.1793	100000	100000	0
2023-03-31	NT Ext Equity Mkt Idx Fd - NL	0.0966	0.0011	73626	0	0
2023-02-28	Fidelity® Series Total Market Index	0.0893	0.0001	68049	0	0
2023-03-31	Northern Trust Extended Eq Market Idx	0.0846	0.001	64482	11167	20.9453
2023-03-31	NT Ext Equity Mkt Idx Fd - L	0.0846	0.001	64482	11167	20.9453
2023-03-31	NT Ext Equity Mkt Idx Fd - DC - NL - T2	0.0817	0.0012	62313	2543	4.2546
2023-03-31	Vanguard Instl Ttl Stk Mkt Idx InstlPls	0.0814	0.0002	62061	0	0
2023-03-31	PVG Emerging Healthcare	0.0803	6.0571	61175	1860	3.1358
2023-03-31	Vanguard Balanced Index Inv	0.0783	0.0001	59700	0	0
2023-03-31	iShares Core S&P Total US Stock Mkt ETF	0.0734	0.0001	55958	30	0.0536
2023-02-28	Fidelity® NASDAQ Composite Index®	0.0526	0.0003	40121	0	0
2023-03-31	State St US Extended Mkt Indx NL Cl C	0.0439	0.001	33500	0	0
2023-03-31	SSgA U.S. Extended Market Index Class I	0.0439	0.001	33500	0	0
2023-02-28	Spartan Total Market Index Pool E	0.0438	0.0001	33390	0	0
Total		8.8037	6.2601	6711012	+126767	+1.9%

3.3. Insider Transactions

Insiders are holding 0.146% of the shares of Hepion Pharmaceuticals Inc.

Date	Owner	Type	Amount	Price	Post Transaction Amount
2021-02-18	John T Cavan	BUY	10000	2
2021-02-18	Robert T Foster	BUY	20000	2
2020-12-18	Peter Wijngaard	BUY	20000	1.91	20000
2020-12-08	Robert T Foster	BUY	25000	1.58
2020-12-01	Gary S Jacob	BUY	12000	1.66	12059
2020-11-25	John T Cavan	BUY	4500	1.62	4800

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Hepion Pharmaceuticals Inc compared to the Most Recent Quarter (MRQ).

	End of day	+/-	Most Recent Quarter	Trailing 12 Months	+/-	Year-Over-Year	+/-	5 Year	+/-	10 Year	+/-
Book Value Change Per Share	-	-	0.000	-0.121	+82701218%	-0.101	+69566068%	0.031	-100%	0.017	-100%
Book Value Growth	-	-	1.000	0.875	+14%	0.927	+8%	2.731	-63%	2.604	-62%
Book Value Per Share	-	-	0.654	0.742	-12%	1.289	-49%	0.578	+13%	0.310	+111%
Book Value Per Share Growth	-	-	1.000	0.875	+14%	0.927	+8%	2.731	-63%	2.604	-62%
Current Ratio	-	-	7.164	7.261	-1%	14.280	-50%	9.674	-26%	6.870	+4%
Debt To Asset Ratio	-	-	0.172	0.172	+0%	0.088	+95%	0.309	-44%	2.165	-92%
Debt To Equity Ratio	-	-	0.208	0.209	0%	0.097	+114%	0.999	-79%	1.131	-82%
Dividend Per Share	-	-	0.000	0.000	+300%	0.000	-38%	0.000	+49%	0.000	+191%
Eps	-	-	-0.089	-0.138	+54%	-0.110	+23%	-0.085	-5%	-0.063	-30%
Eps Growth	-	-	1.000	0.725	+38%	0.941	+6%	0.729	+37%	-2.121	+312%
Free Cash Flow Per Share	-	-	-0.063	-0.097	+54%	-0.112	+77%	-0.069	+9%	-0.055	-13%
Free Cash Flow Per Share Growth	-	-	1.000	1.051	-5%	0.772	+30%	0.888	+13%	0.797	+26%
Free Cash Flow To Equity Per Share	-	-	-0.104	-0.118	+13%	-0.132	+26%	0.029	-464%	0.016	-745%
Free Cash Flow To Equity Per Share Growth	-	-	1.000	1.019	-2%	0.360	+178%	2.352	-57%	1.678	-40%
Gross Profit Margin	-	-	1.000	1.000	0%	1.000	0%	1.000	0%	1.000	0%
Intrinsic Value_10Y_max	-	-	-1.271	-	-	-	-	-	-	-	-
Intrinsic Value_10Y_min	-	-	-10.099	-	-	-	-	-	-	-	-
Intrinsic Value_1Y_max	-	-	-0.328	-	-	-	-	-	-	-	-
Intrinsic Value_1Y_min	-	-	-0.498	-	-	-	-	-	-	-	-
Intrinsic Value_3Y_max	-	-	-0.833	-	-	-	-	-	-	-	-
Intrinsic Value_3Y_min	-	-	-1.951	-	-	-	-	-	-	-	-
Intrinsic Value_5Y_max	-	-	-1.154	-	-	-	-	-	-	-	-
Intrinsic Value_5Y_min	-	-	-3.889	-	-	-	-	-	-	-	-
Net Profit Margin	-	-	-	-	0%	-	0%	-	0%	-	0%
Operating Margin	-	-	-	-	0%	-	0%	-	0%	-	0%
Operating Ratio	-	-	-	-	0%	-	0%	-	0%	-	0%
Pb Ratio	18.226	+93%	1.187	0.736	+61%	1.142	+4%	1.026	+16%	-0.570	+148%
Pe Ratio	-133.401	-1435%	-8.690	-4.687	-46%	-13.850	+59%	-32.943	+279%	-32.064	+269%
Peg Ratio	-	-	-8.690	-2.961	-66%	-15.775	+82%	-19.153	+120%	-18.412	+112%
Price Per Share	11.920	+93%	0.777	0.539	+44%	1.485	-48%	1.709	-55%	1.553	-50%
Price To Total Gains Ratio	181328.151	+93%	11812.190	2950.680	+300%	-15.253	+100%	126.284	+9254%	151.750	+7684%
Profit Growth	-	-	1.000	0.694	+44%	0.944	+6%	0.805	+24%	-1.997	+300%
Quick Ratio	-	-	6.491	4.937	+31%	10.525	-38%	8.315	-22%	6.032	+8%
Return On Assets	-	-	-0.113	-0.147	+30%	-0.081	-28%	-0.134	+19%	-0.898	+694%
Return On Equity	-	-	-0.137	-0.178	+31%	-0.089	-35%	-0.295	+116%	-0.513	+275%
Total Gains Per Share	-	-	0.000	-0.121	+183568%	-0.101	+154290%	0.031	-100%	0.017	-100%
Total Gains Per Share Growth	-	-	2.001	0.843	+137%	0.720	+178%	1.742	+15%	-4.905	+345%
Usd Book Value	-	-	49855937.000	56572784.250	-12%	98248859.250	-49%	44084536.250	+13%	23605234.179	+111%
Usd Book Value Change Per Share	-	-	0.000	-0.121	+82701218%	-0.101	+69566068%	0.031	-100%	0.017	-100%
Usd Book Value Per Share	-	-	0.654	0.742	-12%	1.289	-49%	0.578	+13%	0.310	+111%
Usd Dividend Per Share	-	-	0.000	0.000	+300%	0.000	-38%	0.000	+49%	0.000	+191%
Usd Eps	-	-	-0.089	-0.138	+54%	-0.110	+23%	-0.085	-5%	-0.063	-30%
Usd Free Cash Flow	-	-	-4813837.000	-7415508.500	+54%	-8513210.750	+77%	-5241903.450	+9%	-4192270.179	-13%
Usd Free Cash Flow Per Share	-	-	-0.063	-0.097	+54%	-0.112	+77%	-0.069	+9%	-0.055	-13%
Usd Free Cash Flow To Equity Per Share	-	-	-0.104	-0.118	+13%	-0.132	+26%	0.029	-464%	0.016	-745%
Usd Price Per Share	11.920	+93%	0.777	0.539	+44%	1.485	-48%	1.709	-55%	1.553	-50%
Usd Profit	-	-	-6811474.000	-10519320.250	+54%	-8707921.750	+28%	-5524438.400	-19%	-4300549.615	-37%
Usd Revenue	-	-	-	-	0%	-	0%	-	0%	-	0%
Usd Total Gains Per Share	-	-	0.000	-0.121	+183568%	-0.101	+154290%	0.031	-100%	0.017	-100%
	EOD	+3 -2	MRQ	TTM	+27 -9	YOY	+21 -15	5Y	+18 -18	10Y	+17 -19

4.2. Fundamental Score

Let's check the fundamental score of Hepion Pharmaceuticals Inc based on Penke's default stock scanner.

Penke's Stock Scanner

Indicator	Condition		Value
Price to Earnings Ratio (EOD)	Between	0-15	-133.401
Price to Book Ratio (EOD)	Between	0-1	18.226
Net Profit Margin (MRQ)	Greater than	0	0.000
Operating Margin (MRQ)	Greater than	0	0.000
Quick Ratio (MRQ)	Greater than	1	6.491
Current Ratio (MRQ)	Greater than	1	7.164
Debt to Asset Ratio (MRQ)	Less than	1	0.172
Debt to Equity Ratio (MRQ)	Less than	1	0.208
Return on Equity (MRQ)	Greater than	0.15	-0.137
Return on Assets (MRQ)	Greater than	0.05	-0.113
Total			4/10 (40.0%)

Create your own Stock Scanner

Investing is personal. The best investors buy stocks based on their own analysis. Create your personal Stock Scanner with the key performance indicators that are important to you.
Create your own Stock Scanner

4.3. Technical Score

Let's check the technical score of Hepion Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

Indicator	Condition		Value
Open	Greater than	Close	12.010
Total			1/1 (100.0%)

Create your own Symbol Scanner

Trading is personal. The best traders buy and sell based on their own technical analysis. Create your personal Symbol Scanner with the technical indicators that are important to you.
Create your own Symbol Scanner

Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

		2022-03-31		2022-06-30		2022-09-30		2022-12-31		2023-03-31
Common Stock Shares Outstanding		76,229	1	76,230	0	76,230	0	76,230	-76,230	0

Latest Balance Sheet

Balance Sheet of 2023-03-31. Currency in USD. All numbers in thousands.

Summary

Total Assets	60,244
Total Liabilities	10,389
Total Stockholder Equity	49,856

	As reported
Total Liabilities	10,389
Total Stockholder Equity	+ 49,856
Total Assets	= 60,244

Assets

Total Assets	60,244
Total Current Assets	56,496
Long-term Assets	56,496

Total Current Assets

Total Current Assets (as reported)	56,496
Cash And Cash Equivalents	51,189
Other Current Assets	5,307
Total Current Assets (calculated)	56,496
+/-	0

Long-term Assets

Long-term Assets (as reported)	3,748
Property Plant Equipment	132
Intangible Assets	3,190
Long-term Assets Other	426
Long-term Assets (calculated)	3,748
+/-	0

Liabilities & Shareholders' Equity

Total Current Liabilities	7,886
Long-term Liabilities	2,503
Total Stockholder Equity	49,856

Total Current Liabilities

Total Current Liabilities (as reported)	7,886
Short-term Debt	54
Accounts payable	2,666
Other Current Liabilities	5,166
Total Current Liabilities (calculated)	7,886
+/-	0

Long-term Liabilities

Long-term Liabilities (as reported)	2,503
Long-term Liabilities Other	2,094
Deferred Long Term Liability	409
Long-term Liabilities (calculated)	2,503
+/-	0

Total Stockholder Equity

Total Stockholder Equity (as reported)	49,856
Common Stock	8
Retained Earnings	-175,701
Accumulated Other Comprehensive Income	-90
Capital Surplus	223,944
Total Stockholder Equity (calculated)	48,160
+/-	1,696

Other

Cash and Short Term Investments	51,189
Common Stock Shares Outstanding	0
Common Stock Total Equity	8
Liabilities and Stockholders Equity	60,244
Net Debt	-51,135
Net Tangible Assets	44,970
Preferred Stock Total Equity	1,696
Short Long Term Debt Total	54

Balance Sheet

Currency in USD. All numbers in thousands.

Trend

2023-03-31

2022-12-31

2022-09-30

2022-06-30

2022-03-31

2021-12-31

2021-09-30

2021-06-30

2021-03-31

2020-12-31

2020-09-30

2020-06-30

2020-03-31

2019-12-31

2019-09-30

2019-06-30

2019-03-31

2018-12-31

2018-09-30

2018-06-30

2018-03-31

2017-12-31

2017-09-30

2017-06-30

2017-03-31

2016-12-31

2016-09-30

2016-06-30

2016-03-31

2015-12-31

2015-09-30

2015-06-30

2015-03-31

2014-12-31

2014-09-30

2014-06-30

2014-03-31

2013-12-31

2013-09-30

> Total Assets

76
9
2,643
2,001
1,005
8,965
9,500
5,377
2,854
10,646
6,750
13,107
8,816
16,068
11,760
18,385
14,121
11,250
9,396
7,975
14,381
8,189
7,905
23,339
21,073
20,433
20,433
24,084
20,364
48,645
123,757
119,753
111,602
103,552
95,855
83,566
69,697
60,244
60,244

60,244

69,697

83,566

95,855

103,552

111,602

119,753

123,757

48,645

20,364

24,084

20,433

21,073

23,339

7,905

8,189

14,381

7,975

9,396

11,250

14,121

18,385

11,760

16,068

8,816

13,107

6,750

10,646

2,854

5,377

9,500

8,965

1,005

2,001

2,643

> Total Current Assets

76
9
2,628
1,982
893
8,851
9,362
5,244
2,720
10,518
6,626
7,895
3,613
10,859
6,559
13,193
8,937
6,060
4,149
2,741
9,155
2,968
1,913
17,389
15,185
14,389
14,389
18,169
14,352
42,634
117,745
113,673
105,500
97,452
89,774
79,534
65,670
56,496
56,496

56,496

65,670

79,534

89,774

97,452

105,500

113,673

117,745

42,634

14,352

18,169

14,389

15,185

17,389

1,913

2,968

9,155

2,741

4,149

6,060

8,937

13,193

6,559

10,859

3,613

7,895

6,626

10,518

2,720

5,244

9,362

8,851

893

1,982

2,628

Cash And Cash Equivalents

76
3
2,510
1,818
735
8,792
8,901
4,563
1,791
9,832
5,957
7,404
3,028
10,552
6,137
12,983
8,779
5,950
3,998
2,580
9,032
2,832
1,683
17,149
14,864
13,923
13,923
17,562
13,711
40,727
115,449
110,091
98,731
91,349
79,223
71,708
59,145
51,189
51,189

51,189

59,145

71,708

79,223

91,349

98,731

110,091

115,449

40,727

13,711

17,562

13,923

14,864

17,149

1,683

2,832

9,032

2,580

3,998

5,950

8,779

12,983

6,137

10,552

3,028

7,404

5,957

9,832

1,791

4,563

8,901

8,792

735

1,818

2,510

Other Current Assets

0
6
117
164
158
60
460
681
929
685
670
491
585
307
421
210
159
0
151
161
123
136
230
240
321
0
466
607
641
1,907
2,296
3,582
6,769
0
10,552
7,826
6,524
0
5,307

5,307

6,524

7,826

10,552

6,769

3,582

2,296

1,907

641

607

466

321

240

230

136

123

161

151

159

210

421

307

585

491

670

685

929

681

460

158

164

117

> Long-term Assets

0
0
16
19
111
113
138
133
134
129
123
5,212
5,203
5,209
5,201
5,192
5,184
5,190
5,247
5,234
5,226
5,221
5,991
5,950
5,889
6,044
6,044
5,915
6,011
6,011
6,012
6,080
6,101
6,101
6,081
4,032
4,028
3,748
3,748

3,748

4,028

4,032

6,081

6,101

6,080

6,012

6,011

5,915

6,044

5,889

5,950

5,991

5,221

5,226

5,234

5,247

5,190

5,184

5,192

5,201

5,209

5,203

5,212

123

129

134

133

138

113

111

Property Plant Equipment

0
0
16
15
56
62
87
81
83
77
72
81
74
80
72
68
62
60
46
42
37
32
790
749
700
855
855
725
660
665
666
599
545
456
368
275
183
0
132

132

183

275

368

456

545

599

666

665

660

725

855

700

749

790

Goodwill

0
0
0
0
0
0
0
0
0
0
0
1,871
1,871
1,871
1,871
1,871
1,871
1,870
1,871
1,871
1,871
1,871
1,871
1,871
1,871
1,871
1,871
1,871
1,871
1,871
1,871
1,871
1,871
1,871
1,871
0
0
0
0

1,871

1,870

1,871

Intangible Assets

0
0
0
0
0
0
0
0
0
0
0
3,190
3,190
3,190
3,190
3,190
3,190
3,190
3,190
3,190
3,190
3,190
3,190
3,190
3,190
3,190
3,190
3,190
3,190
3,190
3,190
3,190
3,190
3,190
3,190
3,190
3,190
3,190
3,190

3,190

Other Assets

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,322
3,318
3,318
141
3,331
3,318
3,318
3,318
3,318
3,481
4,032
285
420
495
583
652
568
655
0
0

655

568

652

583

495

420

285

4,032

3,481

3,318

3,331

141

3,318

3,322

> Total Liabilities

399
499
9,986
4,934
465
361
1,616
1,938
4,215
5,662
5,454
11,789
11,812
10,190
12,145
9,327
9,128
7,550
6,345
8,727
9,727
6,214
7,259
5,310
4,847
4,250
4,250
5,792
7,491
8,125
6,182
9,032
8,959
10,557
9,219
16,246
10,438
10,389
10,389

10,389

10,438

16,246

9,219

10,557

8,959

9,032

6,182

8,125

7,491

5,792

4,250

4,847

5,310

7,259

6,214

9,727

8,727

6,345

7,550

9,128

9,327

12,145

10,190

11,812

11,789

5,454

5,662

4,215

1,938

1,616

361

465

4,934

9,986

499

399

> Total Current Liabilities

399
499
260
459
465
361
1,616
1,938
4,215
3,761
4,289
5,084
5,162
3,224
2,474
2,945
2,811
2,600
2,563
5,000
5,653
2,850
3,457
1,798
1,505
1,252
1,252
2,603
3,956
4,662
2,867
7,102
7,082
8,206
6,260
13,377
7,489
7,886
7,886

7,886

7,489

13,377

6,260

8,206

7,082

7,102

2,867

4,662

3,956

2,603

1,252

1,505

1,798

3,457

2,850

5,653

5,000

2,563

2,600

2,811

2,945

2,474

3,224

5,162

5,084

4,289

3,761

4,215

1,938

1,616

361

465

459

260

499

399

Short-term Debt

0
0
0
0
0
0
0
0
0
0
0
10
0
0
0
0
0
0
0
2,000
2,070
1,440
2,093
981
521
0
267
275
275
280
388
286
285
0
247
177
106
0
54

106

177

247

285

286

388

280

275

267

521

981

2,093

1,440

2,070

2,000

Short Long Term Debt

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,903
790
330
0
0
0
0
0
177
0
0
0
0
0
0
0
0

177

330

790

1,903

Accounts payable

28
56
188
244
213
114
1,313
1,481
3,196
3,162
3,441
4,252
4,397
2,303
1,563
1,627
1,483
0
1,732
2,079
2,216
748
707
283
675
492
492
972
1,297
3,722
1,662
3,087
1,794
2,446
2,383
8,912
2,627
2,666
2,666

2,666

2,627

8,912

2,383

2,446

1,794

3,087

1,662

3,722

1,297

972

492

675

283

707

748

2,216

2,079

1,732

1,483

1,627

1,563

2,303

4,397

4,252

3,441

3,162

3,196

1,481

1,313

114

213

244

188

Other Current Liabilities

371
443
72
215
251
247
303
457
1,019
599
847
821
765
921
911
1,318
1,328
0
831
920
1,367
661
657
535
308
0
494
1,356
2,384
660
817
3,729
5,004
2,988
3,629
4,288
4,757
366
5,166

5,166

366

4,757

4,288

3,629

2,988

5,004

3,729

817

660

2,384

1,356

494

308

535

657

661

1,367

920

831

1,328

1,318

911

921

765

821

847

599

1,019

457

303

247

251

215

443

371

> Long-term Liabilities

28
56
9,726
4,475
213
114
1,313
1,481
3,196
1,901
1,166
6,706
6,650
6,966
9,672
6,382
6,318
4,950
3,782
3,727
4,074
3,364
3,802
3,512
3,342
2,998
2,998
3,188
3,535
3,463
3,315
1,930
1,876
2,351
2,959
2,869
2,949
2,503
2,503

2,503

2,949

2,869

2,959

2,351

1,876

1,930

3,315

3,463

3,535

3,188

2,998

3,342

3,512

3,802

3,364

4,074

3,727

3,782

4,950

6,318

6,382

9,672

6,966

6,650

6,706

1,166

1,901

3,196

1,481

1,313

114

213

4,475

9,726

Long term Debt Total

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
177
0
0
0
0
0
0
0
0
0

177

Other Liabilities

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,727
4,074
3,364
3,259
3,010
2,881
2,454
2,494
2,594
3,000
2,991
3,014
1,764
1,777
2,301
2,959
2,869
2,949
0
0

2,949

2,869

2,959

2,301

1,777

1,764

3,014

2,991

3,000

2,594

2,494

2,454

2,881

3,010

3,259

3,364

4,074

3,727

Deferred Long Term Liability

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,190
3,190
3,190
3,203
3,190
3,190
3,190
3,190
3,190
3,190
3,190
414
413
0
0
0
0
0
0
409

409

413

414

3,190

3,203

3,190

> Total Stockholder Equity

-323
-490
-7,342
-2,933
540
8,604
7,884
3,439
-1,361
4,984
1,295
1,318
-2,996
5,878
-385
9,058
4,993
0
3,052
-752
4,654
1,975
645
18,029
16,227
16,183
16,183
18,292
12,873
40,520
117,575
110,721
102,643
92,995
86,636
67,320
59,259
49,856
49,856

49,856

59,259

67,320

86,636

92,995

102,643

110,721

117,575

40,520

12,873

18,292

16,183

16,227

18,029

645

1,975

4,654

-752

3,052

4,993

9,058

-385

5,878

-2,996

1,318

1,295

4,984

-1,361

3,439

7,884

8,604

540

-2,933

-7,342

-490

-323

Common Stock

1
1
2
2
2
2
2
2
2
3
3
3
6
6
6
8
8
0
8
1
2
2
2
0
0
0
0
1
1
3
8
8
8
8
8
8
8
0
8

Retained Earnings

-175,701

-168,890

-160,342

-140,431

-133,501

-127,095

-117,828

-110,163

-104,105

-99,150

-92,349

-83,186

-81,288

-79,469

-78,448

-76,464

-73,891

-73,734

-69,705

-67,010

-65,278

-59,504

-61,554

-53,935

-49,429

-44,612

-39,406

-35,489

-32,458

-27,614

-22,239

-14,841

-6,892

-5,421

-9,802

-491

-323

Capital Surplus

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
77,462
76,651
77,327
95,773
95,798
97,651
104,459
0
0
142,911
226,022
226,834
0
0
0
0
0
0
223,944

223,944

226,834

226,022

142,911

104,459

97,651

95,798

95,773

77,327

76,651

77,462

Treasury Stock

Other Stockholders Equity

-1
0
2,458
2,486
7,429
12,742
16,420
17,351
17,395
26,770
26,999
32,227
44,597
58,575
60,122
67,514
69,223
0
71,708
72,126
77,462
76,651
77,327
95,773
95,798
3
97,651
108,924
110,310
142,911
226,022
226,834
228,023
0
225,354
225,989
226,535
0
223,944

223,944

226,535

225,989

225,354

228,023

226,834

226,022

142,911

110,310

108,924

97,651

95,798

95,773

77,327

76,651

77,462

72,126

71,708

69,223

67,514

60,122

58,575

44,597

32,227

26,999

26,770

17,395

17,351

16,420

12,742

7,429

2,486

2,458

-1

Balance Sheet

Currency in USD. All numbers in thousands.

	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31
Accounts Payable	2,666	2,446	3,722	492	748	1,627	4,252	1,481	244	-	4
Accumulated Other Comprehensive Income	-90	-	-	-	-	-	-	-	-	-	-
Capital Lease Obligations	54	317	576	807	-	-	0	10	-	-	-
Capital Stock	1,704	1,709	1,715	1,717	1,788	-	-	-	-	-	-
Capital Surpluse	223,944	-	142,911	97,651	76,651	69,670	67,514	32,227	17,351	-	-
Cash	51,189	91,349	40,727	13,923	2,832	12,983	7,404	4,563	1,818	1,818	87
Cash And Short Term Investments	51,189	91,349	40,727	13,923	2,832	12,983	7,404	4,563	1,818	-	87
Common Stock	8	8	3	0	2	8	3	2	2	-	1
Common Stock Shares Outstanding	0	70,292	9,678	2,043	184	104	48	39	23	23	33
Common Stock Total Equity	8	-	3	0	2	8	3	2	2	2	1
Deferred Long Term Liab	409	-	3,190	3,190	3,190	3,190	3,190	3,190	-	-	-
Good Will	0	1,871	1,871	1,871	1,871	1,871	1,871	1,871	-	-	-
Intangible Assets	3,190	3,190	3,190	3,190	3,190	3,190	3,190	3,190	-	-	-
Liabilities And Stockholders Equity	60,244	103,552	48,645	20,433	8,189	18,385	13,107	5,377	2,001	2,001	87
Long Term Debt	-	-	177	-	-	-	-	-	-	-	-
Long Term Debt Total	-	-	177	-	-	-	-	-	-	-	-
Net Debt	-51,135	-91,032	-39,975	-13,116	-1,392	-12,983	-7,394	-4,563	-1,818	-1,818	-87
Net Invested Capital	48,160	91,294	38,985	14,466	1,629	-	8,018	-	-	-	-
Net Tangible Assets	44,970	86,233	36,937	12,598	-1,682	792	6,147	-14,253	-	-	-
Net Working Capital	48,610	89,245	37,972	13,137	118	-	10,248	-	-	-	-
Non Current Assets Total	3,748	6,101	6,011	6,044	5,221	5,192	5,212	133	19	-	-
Non Current Liabilities Other	2,094	1,892	2,570	2,433	2,590	-	3,410	3,320	-	-	-
Non Current Liabilities Total	2,503	2,351	3,463	2,998	3,364	6,382	6,706	1,481	4,475	-	4
Non Currrent Assets Other	426	583	285	128	128	63	70	51	4	4	-
Other Assets	-	583	4,032	3,318	3,318	3,263	3,253	70	51	-	-
Other Current Assets	5,307	6,103	1,907	466	136	210	491	681	164	-	-
Other Current Liab	5,166	5,494	660	494	661	1,318	821	457	215	-	224
Other Liab	-	2,301	2,991	2,454	3,364	4,946	6,382	6,706	-	-	-
Other Stockholder Equity	223,944	224,788	142,911	97,651	76,651	67,514	32,227	17,351	2,486	-	-1
Preferred Stock Total Equity	1,696	-	1,712	-	-	-	-	-	-	-	-
Property Plant And Equipment Gross	-	-	108	855	32	68	81	81	15	15	-
Property Plant And Equipment Net	132	456	665	855	32	68	81	81	15	-	-
Property Plant Equipment	82	456	665	855	32	57	68	81	81	-	-
Retained Earnings	-175,701	-133,501	-104,105	-83,186	-76,464	-59,504	-44,612	-27,614	-5,421	-5,421	-140
Retained Earnings Total Equity	-175,701	-	-104,105	-	-	-	-	-	-	-	-
Short Long Term Debt	-	-	-	-	1,440	-	-	-	-	-	-
Short Long Term Debt Total	54	317	752	807	1,440	-	10	10	-	-	-
Short Term Debt	54	267	280	267	1,440	-	10	-	-	-	-
Total Assets	60,244	103,552	48,645	20,433	8,189	18,385	13,107	5,377	2,001	2,001	87
Total Current Assets	56,496	97,452	42,634	14,389	2,968	13,193	7,895	5,244	1,982	1,982	87
Total Current Liabilities	7,886	8,206	4,662	1,252	2,850	2,945	5,084	1,938	459	459	227
Total Liab	10,389	10,557	8,125	4,250	6,214	9,327	11,789	1,938	4,934	4,934	227
Total Stockholder Equity	49,856	92,995	40,520	16,183	1,975	9,058	1,318	3,439	-2,933	-	-140

	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30
Accounts Payable	2,666	2,666	2,627	8,912	2,383	2,446	1,794	3,087	1,662	3,722	1,297	972	492	492	675	283	707	748	2,216	2,079	1,732	-	1,483	1,627	1,563	2,303	4,397	4,252	3,441	3,162	3,196	1,481	1,313	114	213	244	188	56	28
Accumulated Other Comprehensive Income	-90	-	-90	-30	9	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Capital Lease Obligations	-	54	106	177	247	317	384	453	512	576	634	693	745	807	652	693	733	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Capital Stock	-	1,704	1,704	1,704	1,704	1,709	1,715	1,715	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Capital Surpluse	223,944	-	-	-	-	-	-	226,834	226,022	142,911	-	-	104,459	97,651	95,798	95,773	77,327	76,651	77,462	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash	51,189	51,189	59,145	71,708	79,223	91,349	98,731	110,091	115,449	40,727	13,711	17,562	13,923	13,923	14,864	17,149	1,683	2,832	9,032	2,580	3,998	5,950	8,779	12,983	6,137	10,552	3,028	7,404	5,957	9,832	1,791	4,563	8,901	8,792	735	1,818	2,510	3	76
Cash And Short Term Investments	51,189	-	59,145	71,708	79,223	-	98,731	110,091	115,449	40,727	13,711	17,562	13,923	13,923	14,864	17,149	1,683	2,832	9,032	2,580	3,998	-	8,779	12,983	6,137	10,552	3,028	7,404	5,957	9,832	1,791	4,563	8,901	8,792	735	1,818	2,510	3	76
Common Stock	8	-	8	8	8	8	8	8	8	3	1	1	0	0	0	0	2	2	2	1	8	-	8	8	6	6	6	3	3	3	2	2	2	2	2	2	2	1	1
Common Stock Shares Outstanding	0	76,230	76,230	76,230	76,229	76,225	76,225	76,225	52,161	52,161	9,025	8,495	4,346	4,346	3,454	860	250	202	202	152	145	140	137	137	113	107	68	68	49	48	40	40	40	40	36	36	26	33	33
Common Stock Total Equity	8	-	-	-	-	-	-	8	8	3	1	1	0	0	0	0	2	2	2	1	8	10	8	8	6	6	6	3	3	3	2	2	2	2	2	2	2	1	1
Deferred Long Term Liab	409	-	-	-	-	-	-	413	414	3,190	3,190	3,190	3,190	3,190	3,190	3,190	3,203	3,190	3,190	3,190	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Good Will	-	0	0	0	1,871	1,871	1,871	1,871	1,871	1,871	1,871	1,871	1,871	1,871	1,871	1,871	1,871	1,871	1,871	1,871	1,871	1,870	1,871	1,871	1,871	1,871	1,871	1,871	-	-	-	-	-	-	-	-	-	-	-
Intangible Assets	3,190	3,190	3,190	3,190	3,190	3,190	3,190	3,190	3,190	3,190	3,190	3,190	3,190	3,190	3,190	3,190	3,190	3,190	3,190	3,190	3,190	3,190	3,190	3,190	3,190	3,190	3,190	3,190	-	-	-	-	-	-	-	-	-	-	-
Liabilities And Stockholders Equity	60,244	-	69,697	83,566	95,855	-	111,602	119,753	123,757	48,645	20,364	24,084	20,433	20,433	21,073	23,339	7,905	8,189	14,381	7,975	9,396	11,250	14,121	18,385	11,760	16,068	8,816	13,107	6,750	10,646	2,854	5,377	9,500	8,965	1,005	2,001	2,643	9	76
Long Term Debt	-	-	-	-	-	-	-	-	-	177	177	177	-	-	-	-	543	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Long Term Debt Total	-	-	-	-	-	-	-	-	-	177	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Debt	-51,135	-	-59,040	-71,531	-78,975	-	-98,347	-109,638	-114,761	-39,975	-12,901	-16,692	-13,116	-13,116	-13,882	-15,666	954	-1,392	-6,962	-580	-3,998	-5,950	-8,779	-12,983	-6,137	-10,552	-3,028	-7,394	-5,957	-9,832	-1,791	-4,563	-8,901	-8,792	-735	-1,818	-2,510	347	124
Net Invested Capital	-	48,160	57,563	65,624	84,940	91,294	100,936	109,014	116,044	38,985	11,337	16,752	17,051	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Tangible Assets	44,970	-	54,373	62,434	79,879	86,233	95,875	103,953	110,806	36,937	9,290	14,704	15,180	12,598	12,639	14,434	-2,990	-1,682	1,701	-3,478	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Working Capital	-	48,610	58,180	66,157	83,514	89,245	98,418	106,572	114,877	37,972	10,397	15,566	15,772	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Non Current Assets Total	3,748	3,748	4,028	4,032	6,081	6,101	6,101	6,080	6,012	6,011	6,011	5,915	6,044	6,044	5,889	5,950	5,991	5,221	5,226	5,234	5,247	5,190	5,184	5,192	5,201	5,209	5,203	5,212	123	129	134	133	138	113	111	19	16	-	-
Non Current Liabilities Other	2,094	2,094	2,540	2,460	2,550	1,892	1,367	1,351	2,900	2,570	2,560	2,510	2,460	2,433	2,520	2,640	2,690	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Non Current Liabilities Total	2,503	2,503	2,949	2,869	2,959	2,351	1,876	1,930	3,315	3,463	3,535	3,188	2,998	2,998	3,342	3,512	3,802	3,364	4,074	3,727	3,782	4,950	6,318	6,382	9,672	6,966	6,650	6,706	1,166	1,901	3,196	1,481	1,313	114	213	4,475	9,726	56	28
Non Currrent Assets Other	426	426	655	568	652	583	495	420	285	285	291	128	128	128	128	141	141	128	128	132	140	-600	61	63	68	68	68	70	51	51	51	51	51	51	56	4	-	-	-
Other Assets	-	-	655	568	652	583	495	420	285	4,032	3,481	3,318	3,318	3,318	3,318	3,331	141	3,318	3,318	3,322	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other Current Assets	5,307	-	6,524	7,826	10,552	-	6,769	3,582	2,296	1,907	641	607	466	-	321	240	230	136	123	161	151	-	159	210	421	307	585	491	670	685	929	681	460	60	158	164	117	6	-
Other Current Liab	5,166	366	4,757	4,288	3,629	2,988	5,004	3,729	817	660	2,384	1,356	494	-	308	535	657	661	1,367	920	831	-	1,328	1,318	911	921	765	821	847	599	1,019	457	303	247	251	215	72	443	371
Other Liab	-	-	2,949	2,869	2,959	2,301	1,777	1,764	3,014	2,991	3,000	2,594	2,494	2,454	2,881	3,010	3,259	3,364	4,074	3,727	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other Stockholder Equity	223,944	-	226,535	225,989	225,354	-	228,023	226,834	226,022	142,911	110,310	108,924	97,651	3	95,798	95,773	77,327	76,651	77,462	72,126	71,708	-	69,223	67,514	60,122	58,575	44,597	32,227	26,999	26,770	17,395	17,351	16,420	12,742	7,429	2,486	2,458	0	-1
Preferred Stock Total Equity	1,696	-	-	-	-	-	-	1,707	1,707	1,712	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Property Plant And Equipment Gross	-	-	-	-	-	-	-	599	666	108	660	725	855	855	700	749	790	32	37	42	46	60	62	68	72	80	74	81	72	77	83	81	87	62	56	15	16	-	-
Property Plant And Equipment Net	132	-	183	275	368	-	545	599	666	665	660	725	855	-	700	749	790	32	37	42	46	-	62	68	72	80	74	81	72	77	83	81	87	62	56	15	16	-	-
Property Plant Equipment	82	-	183	275	368	456	545	599	172	665	660	725	773	855	700	749	790	32	37	42	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-175,701	-175,701	-168,890	-160,342	-140,431	-133,501	-127,095	-117,828	-110,163	-104,105	-99,150	-92,349	-83,186	-83,186	-81,288	-79,469	-78,448	-76,464	-73,891	-73,734	-69,705	-67,010	-65,278	-59,504	-61,554	-53,935	-49,429	-44,612	-39,406	-35,489	-32,458	-27,614	-22,239	-14,841	-6,892	-5,421	-9,802	-491	-323
Retained Earnings Total Equity	-175,701	-	-	-	-	-	-	-117,828	-110,163	-104,105	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Short Long Term Debt	-	-	-	-	-	-	-	-	177	-	-	-	-	-	330	790	1,903	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Short Long Term Debt Total	54	-	106	177	247	-	384	453	688	752	810	869	807	807	982	1,483	2,636	1,440	2,070	2,000	-	-	-	-	-	-	10	10	-	-	-	-	-	-	-	-	-	350	200
Short Term Debt	54	-	106	177	247	-	285	286	388	280	275	275	267	-	521	981	2,093	1,440	2,070	2,000	-	-	-	-	-	-	-	10	-	-	-	-	-	-	-	-	-	-	-
Total Assets	60,244	60,244	69,697	83,566	95,855	103,552	111,602	119,753	123,757	48,645	20,364	24,084	20,433	20,433	21,073	23,339	7,905	8,189	14,381	7,975	9,396	11,250	14,121	18,385	11,760	16,068	8,816	13,107	6,750	10,646	2,854	5,377	9,500	8,965	1,005	2,001	2,643	9	76
Total Current Assets	56,496	56,496	65,670	79,534	89,774	97,452	105,500	113,673	117,745	42,634	14,352	18,169	14,389	14,389	15,185	17,389	1,913	2,968	9,155	2,741	4,149	6,060	8,937	13,193	6,559	10,859	3,613	7,895	6,626	10,518	2,720	5,244	9,362	8,851	893	1,982	2,628	9	76
Total Current Liabilities	7,886	7,886	7,489	13,377	6,260	8,206	7,082	7,102	2,867	4,662	3,956	2,603	1,252	1,252	1,505	1,798	3,457	2,850	5,653	5,000	2,563	2,600	2,811	2,945	2,474	3,224	5,162	5,084	4,289	3,761	4,215	1,938	1,616	361	465	459	260	499	399
Total Liab	10,389	10,389	10,438	16,246	9,219	10,557	8,959	9,032	6,182	8,125	7,491	5,792	4,250	4,250	4,847	5,310	7,259	6,214	9,727	8,727	6,345	7,550	9,128	9,327	12,145	10,190	11,812	11,789	5,454	5,662	4,215	1,938	1,616	361	465	4,934	9,986	499	399
Total Stockholder Equity	49,856	49,856	59,259	67,320	86,636	92,995	102,643	110,721	117,575	40,520	12,873	18,292	16,183	16,183	16,227	18,029	645	1,975	4,654	-752	3,052	-	4,993	9,058	-385	5,878	-2,996	1,318	1,295	4,984	-1,361	3,439	7,884	8,604	540	-2,933	-7,342	-490	-323

Cash Flow

Currency in USD. All numbers in thousands.

	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31
Begin Period Cash Flow	91,349	40,727	13,923	2,832	5,954	7,404	4,563	1,818	87	87
Capital Expenditures	16	130	88	51	51	15	7	83	16	16
Cash And Cash Equivalents Changes	-40,113	-	26,804	-	-	-	-	-	-	-
Cash Flows Other Operating	907	-	-1,410	-	-	-	-	-	-	-
Change In Cash	-40,160	50,622	26,804	11,091	-3,122	5,579	2,841	2,745	1,731	1,731
Change In Working Capital	3,153	-5,567	1,629	-755	-970	-1,841	3,327	953	125	125
Change To Liabilities	2,246	-1,068	3,039	-424	-898	-390	-2,128	3,135	-	-
Change To Netincome	4,009	6,979	2,525	-605	-5,245	-4,423	-2,468	-2,905	-	-
Change To Operating Activities	-	-4,499	-1,410	-330	-73	194	288	192	-	-
Depreciation	77	86	35	27	19	28	22	16	1	1
Dividends Paid	5	11	10	-	-	-	-	-	-	-
End Period Cash Flow	51,189	91,349	40,727	13,923	2,832	12,983	7,404	4,563	1,818	1,818
Free Cash Flow	-34,978	-31,355	-16,253	-7,617	-15,646	-19,187	-16,562	-9,756	-1,379	-1,379
Investments	-14	-130	-86	-51	1	-	-15	-502	-	-
Issuance Of Capital Stock	17,863	82,154	42,866	17,736	12,050	-	-	-	-	-
Net Borrowings	-	-177	177	-1,119	1,331	1,331	-10	-10	-	-
Net Income	-42,200	-32,722	-20,354	-6,719	-9,449	-14,891	-16,999	-14,348	-5,281	-5,281
Other Cashflows From Financing Activities	-1,995	11	189	13,393	11,557	116	19,898	12,501	335	-15
Other Cashflows From Investing Activities	2	-	2	-	1	-	-	-496	-	-
Other Non Cash Items	1,456	2,310	146	157	-4,944	-4,225	-3,807	1,588	3,596	-
Sale Purchase Of Stock	-21,000	-	42,878	19,826	12,192	1,181	24,776	19,898	12,501	-
Stock Based Compensation	2,553	4,669	2,379	66	235	1,756	902	2,118	195	-
Total Cash From Financing Activities	-5,138	81,977	43,055	18,707	12,524	24,766	19,898	12,501	3,110	3,110
Total Cash From Operating Activities	-34,961	-31,224	-16,165	-7,565	-15,646	-19,172	-16,555	-9,673	-1,363	-1,363
Total Cashflows From Investing Activities	-14	-130	-86	-51	1	-2	-15	-502	-83	-

	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30
Begin Period Cash Flow	59,145	59,145	71,708	79,223	91,349	98,731	110,091	115,449	40,727	13,711	17,562	16,048	14,864	14,864	17,149	1,683	2,832	9,032	2,580	3,998	5,954	8,780	12,983	6,137	10,552	3,028	7,404	5,957	9,832	1,791	4,563	8,901	8,792	735	1,818	2,510	3	76	87
Capital Expenditures	16	0	0	0	0	0	36	12	82	77	0	11	6	6	0	7	38	38	38	38	0	0	2	2	0	0	0	0	0	0	7	0	29	10	44	0	0	0	0
Cash And Cash Equivalents Changes	-	-	-	-	-	-	-	-5,358	74,722	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash Flows Other Operating	-	-	-	-	-	-	-	-1,423	-389	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Change In Cash	-7,956	-7,956	-12,562	-7,515	-12,126	-7,382	-11,360	-5,358	74,722	27,016	-3,850	1,514	-941	-941	-2,285	15,466	-1,150	-6,200	6,452	-1,417	-1,956	-2,830	-4,204	6,845	-4,414	7,524	-4,376	1,447	-3,876	8,041	-2,772	-4,338	110	8,056	-1,082	-692	2,507	-73	-11
Change In Working Capital	1,844	1,844	-4,701	10,449	-4,439	749	-4,295	271	-2,292	-560	1,367	1,327	-144	-543	99	-556	-154	-1,202	-334	523	43	-2,667	68	688	-855	-1,660	-14	965	543	-211	2,029	101	854	68	-71	125	-11	-58	70
Change To Liabilities	-	-	-5,886	7,660	76	173	-1,032	1,694	-1,902	701	1,385	675	278	2	166	-546	-46	-1,191	-363	510	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Change To Netincome	-	-	697	1,943	1,216	1,578	2,216	2,203	982	977	1,007	494	48	-409	-89	-113	5	-1,322	-3,057	84	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Change To Operating Activities	-	-	1,185	2,790	-4,515	576	-3,263	-1,423	-389	-1,261	-18	652	-784	-145	-68	-10	-108	-11	28	14	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Depreciation	18	18	18	19	23	23	23	21	18	14	7	7	7	7	7	8	5	5	5	5	5	5	6	7	8	6	7	5	5	5	5	5	5	4	3	-	-	-	-
Dividends Paid	5	-	-	-	11	-	11	10	10	10	10	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
End Period Cash Flow	51,189	51,189	59,145	71,708	79,223	91,349	98,731	110,091	115,449	40,727	13,711	17,562	13,923	13,923	14,864	17,149	1,683	2,832	9,032	2,580	3,998	5,950	8,779	12,983	6,137	10,552	3,028	7,404	5,957	9,832	1,791	4,563	8,901	8,792	735	1,818	2,510	3	76
Free Cash Flow	-4,814	-4,814	-12,534	-7,500	-10,129	-7,382	-11,360	-5,181	-7,431	-4,602	-3,850	-3,123	-2,446	-2,446	-1,803	-1,271	-2,096	-5,092	-3,544	-3,417	-3,592	-2,840	-5,373	-4,251	-5,205	-5,340	-4,378	-4,395	-3,876	-5,485	-2,805	-4,339	-2,890	-1,444	-1,082	-692	-337	-223	-111
Investments	-	-16	0	2	0	0	-36	-12	-82	-77	0	-11	2	-6	0	-7	-38	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Issuance Of Capital Stock	-	17,863	0	0	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Borrowings	-	-	-	-	-	-	-	-177	-177	-177	-177	177	177	-334	-482	-1,250	946	-669	-669	2,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-6,811	-6,811	-8,548	-19,911	-6,930	-9,733	-9,267	-7,665	-6,057	-4,956	-6,232	-4,940	-1,894	-1,894	-1,820	-1,021	-1,984	-2,573	-157	-4,029	-2,690	-1,740	-5,774	2,050	-7,619	-4,505	-4,817	-5,206	-3,917	-3,030	-4,844	-5,375	-4,398	-3,104	-1,470	4,381	-9,312	-168	-182
Other Cashflows From Financing Activities	-20,990	-	-	-5	-2,000	-2,000	-36	-177	-82	-77	0	177	0	-6	0	12,143	1,250	-1,107	9,996	2,000	1	1,169	-2	11,097	791	12,876	2	6,338	1	13,526	33	1	3,000	9,500	-44	-	2,860	150	100
Other Cashflows From Investing Activities	-	-	-	-	-	-	-	-	-	-	-	-	2	-	-	-	-	1	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other Non Cash Items	-80	-80	80	1,781	-325	720	747	808	24	-9	16	100	-81	-86	-106	287	57	-1,124	-3,120	-69	-631	-650	-64	-7,266	2,705	391	-55	-588	-735	-2,484	-	-	-	1,200	388	-5,249	8,842	4	2
Sale Purchase Of Stock	-	-	-	-	-	-	-	-	82,154	-	-	-	6,800	19,826	17,987	17,987	1,250	12,192	11,631	-	10	10	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Stock Based Compensation	232	232	617	163	1,541	848	1,469	1,395	958	986	991	395	14	-	17	17	18	-199	63	153	217	-	391	273	554	428	501	429	228	234	11	929	678	399	112	51	143	-	-
Total Cash From Financing Activities	-3,138	-3,138	0	0	-2,000	-2,000	-2,000	-177	82,154	31,617	11,437	4,637	1,505	1,505	-482	16,737	946	-1,107	9,996	2,000	1,635	10	1,169	11,097	791	12,876	2	6,338	1	13,526	33	1	3,000	9,500	-	-	2,860	150	100
Total Cash From Operating Activities	-4,798	-4,798	-12,534	-7,500	-10,129	-7,382	-11,323	-5,170	-7,349	-4,525	-3,850	-3,111	-2,440	-2,440	-1,803	-1,264	-2,058	-5,092	-3,544	-3,417	-3,592	-2,840	-5,373	-4,249	-5,205	-5,340	-4,378	-4,395	-3,876	-5,485	-2,799	-4,339	-2,861	-1,433	-1,039	-692	-337	-223	-111
Total Cashflows From Investing Activities	-	-	-	2	2	0	-36	-12	-82	-77	0	-11	2	-6	0	-7	-38	-38	-38	-38	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Income Statement

Currency in USD. All numbers in thousands.

	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31
Depreciation And Amortization	1,948	86	35	-153	4,628	4,253	3,828	-372	-3,607	1
Ebit	-45,489	-30,403	-20,146	-7,770	-14,594	-21,024	-20,805	-13,960	-1,672	-1,672
Ebitda	-43,540	-30,317	-20,112	-7,923	-9,967	-16,771	-16,977	-14,332	-5,280	-1,671
Extraordinary Items	-	-	-	-	-500	-400	-	-	-	-
Income Before Tax	-45,084	-32,722	-20,323	-7,946	-9,985	-16,799	-16,999	-14,348	-5,281	-5,281
Income Tax Expense	-2,884	2,319	31	-1,227	-536	-1,908	-3,807	388	3,609	-
Interest Expense	10	9	31	555	4,609	4,225	3,807	388	3,609	0
Interest Income	-	-	-	176	4,609	1,063	4,225	3,807	-	-
Net Income	-42,200	-35,041	-20,354	-6,719	-9,449	-14,891	-13,192	-14,736	-8,890	-5,281
Net Income Applicable To Common Shares	-45,338	-32,722	-20,359	-12,162	-17,901	-13,080	-14,891	-16,999	-22,193	-
Net Income From Continuing Ops	-42,200	-32,722	-20,354	-6,719	-9,449	-13,080	-14,891	-16,999	-	-
Net Interest Income	-10	-9	-31	-555	-339	-	-	-	-	-
Non Recurring	1,871	-	-	-	-	-	-	-	-	-
Operating Income	-45,489	-30,403	-20,146	-7,770	-14,594	-21,024	-20,805	-13,960	-1,672	-1,672
Other Operating Expenses	43,618	30,403	20,146	7,770	14,594	21,024	20,805	13,960	1,672	1,672
Preferred Stock And Other Adjustments	3,138	-	5	-	-	-	-	-	-	-
Reconciled Depreciation	77	86	35	27	19	-	28	-	-	-
Research Development	33,269	20,395	11,997	3,184	7,594	13,652	15,019	8,404	314	314
Selling General Administrative	10,348	10,008	8,149	4,586	7,000	7,372	5,786	5,556	1,358	1,358
Tax Provision	-2,884	0	31	-1,227	-536	-2,348	-1,908	-	-	-
Total Operating Expenses	43,618	30,403	20,146	7,770	14,594	21,024	20,805	13,960	1,672	1,672
Total Other Income Expense Net	405	-2,319	-177	-176	4,609	4,225	3,807	-388	-3,609	-3,596
Total Revenue	0	0	0	0	0	-	0	0	-	-

	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30
Depreciation And Amortization	1,889	-	18	19	23	-	-724	-787	-6	23	-39	-62	88	7	113	164	-57	428	3,700	-140	640	5	70	7,273	-2,702	6	67	593	741	2,489	5	5	5	4	-385	5,251	-8,853	-5	-2
Ebit	-9,773	-	-8,465	-19,998	-7,252	-9,000	-8,517	-6,855	-6,031	-4,953	-6,231	-4,775	-2,242	-2,242	-1,911	-1,696	-1,922	-2,996	-3,853	-3,884	-3,862	-4,680	-5,838	-5,216	-4,908	-6,413	-4,877	-5,794	-4,653	-5,514	-4,844	-5,375	-4,398	-3,104	-1,083	-870	-459	-163	-180
Ebitda	-7,883	-9,674	-8,448	-19,980	-7,230	-9,707	-9,241	-7,641	-6,037	-4,930	-6,270	-4,837	-2,155	-2,236	-1,797	-1,532	-1,979	-2,568	-152	-4,024	-3,222	-4,675	-5,768	2,056	-7,610	-6,407	-4,810	-5,201	-3,912	-3,025	-4,839	-5,370	-4,393	-3,101	-1,468	4,381	-9,312	-168	-182
Extraordinary Items	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-500	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Income Before Tax	-9,695	-9,695	-8,548	-19,911	-6,930	-9,733	-9,267	-7,665	-6,057	-4,959	-6,294	-4,845	-2,161	-2,161	-1,820	-1,982	-1,984	-2,573	-157	-4,029	-3,226	-3,680	-5,774	2,050	-7,619	-6,413	-4,817	-5,206	-3,917	-3,030	-4,844	-5,375	-4,398	-3,104	-1,470	4,381	-9,312	-168	-182
Income Tax Expense	-2,884	-	82	-87	-323	-	749	811	26	-3	-62	96	-266	-266	-91	-961	62	-423	-3,695	145	-536	-2,350	-64	-7,266	2,710	-1,908	-60	-588	-735	-2,484	-	-	-	-	388	-5,251	8,853	5	2
Interest Expense	3	3	2	3	2	2	2	2	2	15	16	69	0	0	15	442	62	423	3,695	145	635	1,000	64	7,266	2,710	-	60	588	735	2,484	-	-	-	-	388	5,251	8,853	5	2
Interest Income	-	-	-	-	-	-	-	-	-	-	-	-	40	82	91	286	62	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-6,811	-6,811	-8,630	-19,824	-6,607	-9,733	-10,016	-8,476	-6,083	-4,956	-6,232	-4,940	-1,894	-1,894	-1,729	-1,021	-2,046	-2,150	3,538	-4,174	-2,690	-1,740	-5,710	9,316	-10,329	-4,505	-4,757	-4,618	-3,182	-547	-4,844	-5,375	-4,398	-3,104	-1,858	9,632	-18,165	-173	-184
Net Income Applicable To Common Shares	-	-	-8,548	-19,911	-6,930	-9,727	-9,267	-7,665	-6,063	-4,956	-6,237	-4,940	-4,227	-1,893	-1,828	-6,433	-2,008	-2,219	-8,963	-4,029	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income From Continuing Ops	-	-6,811	-8,548	-19,911	-6,930	-9,733	-9,267	-7,665	-6,057	-4,956	-6,232	-4,940	-4,227	-1,894	-1,820	-1,021	-1,984	-2,573	-157	-4,029	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Interest Income	-	-3	-2	-3	-2	-2	-2	-2	-2	-15	-16	0	0	0	-15	-442	-98	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Income	-9,773	-7,902	-8,465	-19,998	-7,252	-9,000	-8,517	-6,855	-6,031	-4,953	-6,231	-4,775	-2,242	-2,242	-1,911	-1,696	-1,922	-2,996	-3,853	-3,884	-3,862	-4,680	-5,838	-5,216	-4,908	-6,413	-4,877	-5,794	-4,653	-5,514	-4,844	-5,375	-4,398	-3,104	-1,083	-870	-459	-163	-180
Other Operating Expenses	7,902	-	8,465	19,998	7,252	-	8,517	6,855	6,031	4,953	6,231	4,775	2,242	2,242	1,911	1,696	1,922	2,996	3,853	3,884	3,862	4,680	5,838	5,216	4,908	6,022	4,877	5,794	4,653	5,514	4,844	5,375	4,398	3,104	1,083	870	459	163	180
Preferred Stock And Other Adjustments	-	-	-	-	-	-	-	-	5	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Reconciled Depreciation	-	18	18	19	23	23	23	21	18	14	7	7	7	7	7	8	5	5	5	5	5	5	6	7	8	6	7	5	5	5	5	5	5	4	3	-	-	-	-
Research Development	7,516	7,516	5,740	15,702	4,311	6,910	5,800	4,186	3,499	2,627	3,783	2,950	1,064	1,064	846	756	518	1,042	2,168	2,123	2,261	3,200	3,963	3,260	2,945	4,318	3,130	4,025	3,187	4,042	3,766	3,590	2,606	1,824	384	219	73	9	14
Selling General Administrative	386	386	2,725	4,296	2,941	2,090	2,717	2,669	2,533	2,326	2,448	1,825	1,178	1,178	1,064	940	1,404	1,953	1,685	1,761	1,601	1,480	1,875	1,956	1,964	1,705	1,747	1,770	1,466	1,472	1,079	1,785	1,792	1,281	698	651	386	154	167
Tax Provision	-	-2,884	0	0	0	0	0	0	0	-3	-62	96	0	-266	0	-961	0	-500	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Operating Expenses	7,902	7,902	8,465	19,998	7,252	9,000	8,517	6,855	6,031	4,953	6,231	4,775	2,242	2,242	1,911	1,696	1,922	2,996	3,853	3,884	3,862	4,680	5,838	5,216	4,908	6,022	4,877	5,794	4,653	5,514	4,844	5,375	4,398	3,104	1,083	870	459	163	180
Total Other Income Expense Net	77	-1,791	-82	87	323	-731	-749	-811	-26	-6	-63	-69	82	81	91	-286	-62	423	3,695	-145	635	-1,000	64	7,266	-2,710	-391	60	588	735	2,484	-	-	-	-	-388	5,251	-8,853	-5	-2
Total Revenue	-	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Latest Income Statement (annual, 2022-12-31)

Gross Profit (+$)
totalRevenue	0
Cost of Revenue	--
Gross Profit	-	0

Operating Income (+$)
Gross Profit	-
Operating Expense	-43,618
Operating Income	-45,489	-43,618

Operating Expense (+$)
Research Development	33,269
Selling General Administrative	10,348
Selling And Marketing Expenses	-
Operating Expense	43,618	43,618

Net Interest Income (+$)
Interest Income	-
Interest Expense	-10
Other Finance Cost	-0
Net Interest Income	-10

Pretax Income (+$)
Operating Income	-45,489
Net Interest Income	-10
Other Non-Operating Income Expenses	-
Income Before Tax (EBT)	-45,084	-45,894 EBIT - interestExpense = -45,499 -45,084 -42,190
Interest Expense	10
Earnings Before Interest and Taxes (EBIT)	-45,489	-45,074
Earnings Before Interest and Taxes (EBITDA)	-43,540

After tax Income (+$)
Income Before Tax	-45,084
Tax Provision	--2,884
Net Income From Continuing Ops	-42,200	-42,200
Net Income	-42,200
Net Income Applicable To Common Shares	-45,338

Non-recurring Events
Discontinued Operations	-
Extraordinary Items	-
Effect of Accounting Charges	-
Other Items	-
Non Recurring	1,871
Other Operating Expenses	43,618
Total Other Income/Expenses Net	405	10

Technicals of Hepion Pharmaceuticals Inc

1. Trend Indicators

1.1 Moving Averages

Shows the moving average of the selected period.

Moving averages are lagging trend indicators.
There are many types of moving averages.
Moving averages are also used within other indicators.

Directionalities and relatives.

Moving Average	Amount of candles	Trend	Price +/-	vs. MA 50	vs. MA 100	vs. MA 200

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Shows the moving average of the selected period.

There are four types of indicators:

Trend indicators
Momentum indicators
Volatility indicators
Volume indicators

There are various kinds of moving averages:

Simple moving average (SMA);
Exponential moving average (EMA);
Smoothed moving average (SMMA);
Linear weighted moving average (LWMA).

The moving average looks at a certain period of time and it calculates the price average. The various types of averages are using various formulas. Don’t worry, you don’t have to memorize any formula. All moving averages are calculated automatically by basically every charting software you use. But it’s good to know how moving averages are actually calculated.

Simple moving average

SMA is calculated by summing up the price closures of the selected period. The price is then divided by the selected period. For example, when using the 21 day moving average you sum up all the closing prices for each day and divide that by 21. The result is a line on the chart representing the average. Because it’s an average in the selected timeframe, the trend is always lagging. An moving average looks like this on the chart:

Source: Tradingview.com

In this case, the blue line represents a 21 day moving average. Because the average is based on results from the past, the indicator will always lag behind. For example, when price would suddenly go up, the moving average won't immediately follow.

All other moving averages discussed below look the same on the chart. The only difference is that the line will move in different directions based on the maths behind the used indicators and the amount of days used to determine the average.

Exponential moving average

The EMA gives more weight to the latest closing prices by giving them more value in the equation. EMA is calculated by adding a certain percentage to the latest closing prices:

EMA = (CLOSE (i) * P) + (EMA (i - 1) * (1 - P))

Where:

CLOSE (i) = current period close price.
EMA (i - 1) = value of the Moving Average of a preceding period.
P = the percentage of using the price value.

Smoothed moving average

A smoothed moving average is an exponential moving average with a long lookback period. Older prices are reduced in weight but are never left out in the calculation. Unlike SMA and EMA where prices are removed when they are beyond the selected period. SMMA is a combination of the SMA and EMA. The main advantage is that it smooths out fluctuations in price.

Linear weighted moving average

The LWMA gives the latest price the highest weight and then lineary scales down with each price before that. The result is that the LWMA reacts quicker to changes in price than the SMA or EMA. The formula:

LWMA = ((Pn∗W1)+(Pn−1∗W2)+(Pn−2∗W3)...) / ∑W

Where:

P = Price for the period.
n = The most recent period, n-1 is the prior period, and n-2 is two periods prior.
W = The assigned weight to each period, with the highest weight going first and then descending linearly based on the number of periods being used.

Moving averages are widely used by many traders. Which moving average you need depends on your trading strategy. Common practise is using a combination of multiple periods. For example, the EMA21, EMA50, EMA100 and EMA200. How does that look on a chart:

Source: Tradingview.com

The lowest (purple) line on the chart represents the EMA200 then following up the EMA100, EMA50 and EMA21.

You can use moving averages to determine a trend. The 200 moving average is mostly used as a baseline for determining the current trend:

When the 200 moving average is moving up it is considered a bullish trend.
When the 200 moving average is down it is considered a bearish trend.
When moving averages are flatlined, there is no clear trend so you should look for market structure, consolidation or trend reversals. Depending on how you want to trade.

This is not set in stone. Most trading strategies use multiple moving averages each with different settings. While one strategy might use the EMA20, the other uses the SMA21. There can be hundreds of different variations. Moving averages can also be used as support and resistance. More often than not, prices will bounce on moving averages.

Hepion Pharmaceuticals Inc Daily Moving Averages Chart

1.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

MACD is a lagging momentum indicator.
Uses two moving averages.
Can show buy or sell signals based on momentum.
Can show overbought. and oversold. levels.

Let's take a look of the Moving Average Convergence/Divergence (MACD) of Hepion Pharmaceuticals Inc:

Hepion Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) Chart

1.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index).

The ADX helps you determine the strength of a trend. Let's take a look of the ADX of Hepion Pharmaceuticals Inc:

The ADX is .

Hepion Pharmaceuticals Inc Daily Directional Movement Index (DMI) Chart

1.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

Parabolic SAR (stop and reverse) is a lagging trend indicator.
Shows the current trend.
Shows potential entry signals.
Shows potential exit signals.
Can be used to place trailing stoplosses..

The Parabolic SAR is lower than the price. The current trend is up. +2

Hepion Pharmaceuticals Inc Daily Parabolic SAR Chart

2. Momentum Indicators

2.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

Leading momentum indicator, meaning the signals are instant.
Ranges between 0 and 100.
Above 70 is considered overbought.
Below 30 is considered oversold.
Above or below 50 can also be used to determine price trend or support and resistance.
RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
Can be used in many different ways

The RSI is below 50. -1
The RSI is below 30 and oversold. +2

Measures the speed and change of price movements.

There are four types of indicators:

Trend indicators
Momentum indicators
Volatility indicators
Volume indicators

The RSI measures the magnitude of recent price changes to determine if the asset is overbought or oversold.

Overbought (RSI above 70) means that the trading price is above its intrinsic value. This might indicate a sell or short signal.
Oversold (RSI below 30) means that the trading price is below its intrinsic value. This might indicate a buy or long signal.
RSI levels above or below 50 can also be used to determine a trend.
RSI divergence looks at a deviation between RSI and price movement.
Can be used in many different ways.

Original usage

Keep in mind that almost every indicator can be used in different ways. Even beyond the orginal settings. The relative strength index was developed by J. Welles Wilder. Wilder recommended a smoothing period of 14 days. That means a 14 day moving average (read more about this setting below). Another quote from the wikipedia page:

Wilders also considers the RSI 50 line as both support and resistance. I recommend to always read the original settings first before using an indicator. Many traders and websites are using their own version of the indicator which might be confusing.

How you can use RSI (Divergence)

First and foremost, there is no real right or wrong usage of the RSI indicator. You can use it in any way you want. Wilder recommends using a 14 day average but you can make it 50 or 100 if you like. Just keep in mind that using an indicator is just part of a larger trading plan. In other words, it’s not recommended to do any trading or investing based on a single indicator like the RSI.

The RSI is measured on a scale between 0 and 100. From 30 till 0 is considered oversold. and from 70 -100 is overbought. The RSI is a leading indicator, meaning the signals are instant.

I like to use the RSI as a trend\momentum indicator and not as an overbought or oversold indicator. I use the middle (50) as the baseline. When prices go above RSI 50 the trend is bullish and can indicate long positions. When below 50 it is considered bearish and can indicate short positions. Other traders use the 70 and 30 levels as overbought/oversold depending on the used strategy. The RSI indicator looks like this:

Source: Tradingview.com

The general concensus is that an RSI above 70 indicates that the security is overbought. In other words, the price this security is trading for is to high and should come down. So if RSI hits 70 or above this might indicate a sell signal or taking a short position (expecting the price will go down). Although RSI above 70 indicates the security is trading above it's fair value, that does not mean the price will go down.

Use tradingview to add indicators

I highly recommend using tradingview to add indicators to a chart. It has all the indicators you can think off and can add them for free (up to three indicators) to any chart you want. You can see that the levels 30 and 70 are marked with a dotted line. If you want you can remove these lines or give it another colour using Tradingview. You can also adjust the moving average used. You can also find RSI indicators made by the community that include other settings like RSI divergences.

Tradingview

Use Tradingview to (back)test your strategies and add hundreds of indicators created by the community.

View tool on Tradingview.com

RSI divergence

RSI is not only used to determine momentum but can also spot reversals or continuations of the trend. A reversal means that the trend is going in the opposite direction. From bullish to bearish or from bearish to bullish. These reversals can be spotted by looking at the price and the direction of the RSI. When the price is going up but the RSI is going down that means there is a divergence. This is also the case when RSI goes up but price is going down.

There are four types of divergences:

Regular bullish divergence
Regular bearish divergence
Hidden bullish divergence
Hidden bearish divergence

Regular bullish divergence

With a regular bullish divergence, the price is making lower highs but the oscillator (in this case the RSI) is making higher lows. A regular bullish divergence might indicate the end of the current trend. You’ll see regular bullish divergences mostly at the end of a downtrend. But that does not mean that every regular bullish divergence is a trend reversal.

Price is making lower highs
RSI is making higher lows
Indicating bullish reversal (price might go up)

Source: Tradingview.com

Regular bearish divergence

With a regular bearish divergence the price is making higher highs but the oscillator (in this case the RSI) is making lower highs. This might indicate the end of an uptrend.

Price is making higher highs
RSI is making lower highs
Indicating bearish reversal

Source: Tradingview.com

Hidden bullish divergence

With a hidden bullish divergence, the price is making a higher low while the RSI is making a lower low. This might indicate bullish trend continuation.

Price is making higher lows
RSI is making lower lows
Indicating bullish continuation

Source: Tradingview.com

As you have noticed, you can have multiple divergences in a row.

Hidden bearish divergence

With a hidden bearish divergence, price is making lower highs but RSI is making higher highs. This might indicate bearish trend continuation.

Price is making lower highs
RSI making higher highs
Indicating bearish continuation

Source: Tradingview.com

You can find many cheatsheets of RSI divergences online. Search for "RSI divergence overview" and you'll find a lot of examples. You can print these to learn the various types of divergences.